2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one and 7-amino-1-pyrimido[4,5-d]pyrimidin-2(1 h)-one derivatives as egfr inhibitors for the treatment of cancer

A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein RNA is selected from halo, nitro, cyano, oxo or a group of the formula:

• wherein:
• LNA is absent or (1-2C)alkylene;
• XNA is absent or is selected from the group consisting of —O—, —C(O)—, —NRNA1—, —C(O)—O—, —O—C(O)—, —S(O)0-2—, —C(O)—N(RNA1)—, —N(RNA1)—C(O)—, —O—C(O)—N(RNA1)—, —N(RNA1)—C(O)—O—, —N(RNA2)—C(O)—NRNA1—, —SO2N(RNA1)— or —N(RNA1)SO2—, where RNA1 and RNA2 are independently selected from the group consisting of hydrogen or (1-2C)alkyl;
• LNB is absent or (1-4C)alkylene;
• XNB is absent or is selected from the group consisting of —O—, —C(O)—, —NRNB1—, —C(O)—O—, —O—C(O)—, —S(O)0-2—, —C(O)—N(RNB1)—, —N(RNB1)—C(O)—, —O—C(O)—N(RNB1)—, —N(RNB1)—C(O)—O—, —N(RNB2)—C(O)—NRNB1—, —SO2N(RNB1)— or —N(RNB1)SO2—, where RNB1 and RNB2 are independently selected from the group consisting of hydrogen or (1-2C)alkyl;
• QN is selected from the group consisting of hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl(1-2C)alkyl, phenyl, phenyl(1-2C)alkyl, 3- to 8-membered heterocyclyl, [3- to 8-membered heterocyclyl](1-2C)alkyl, 5- or 6-membered heteroaryl, or [5- or 6-membered heteroaryl](1-2C)alkyl;
• and wherein QN is optionally substituted with one or more RNC groups;
• and each RNC group present is independently selected from the group consisting of hydroxy, cyano, oxo, halogen, (1-2C)alkyl, (1-2C)alkoxy, (3-6C)cycloalkyl, —NRNC1RNC2 or —C(O)—RNC1,
• wherein RNC1 and RNC2 are each independently hydrogen or (1-2C)alkyl.

A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein RNA is selected from halo, nitro, cyano, oxo or a group of the formula:

• wherein:
• LNA is absent or (1-2C)alkylene;
• XNA is absent or is selected from the group consisting of —O—, —C(O)—, —NRNA1—, —C(O)—O—, —O—C(O)—, —S(O)0-2—, —C(O)—N(RNA1)—, —N(RNA1)—C(O)—, —O—C(O)—N(RNA1)—, —N(RNA1)—C(O)—O—, —N(RNA2)—C(O)—NRNA1—, —SO2N(RNA1)— or —N(RNA1)SO2—, where RNA1 and RNA2 are independently selected from the group consisting of hydrogen or (1-2C)alkyl;
• LNB is absent or (1-4C)alkylene;
• XNB is absent or is selected from the group consisting of —O—, —C(O)—, —NRNB1—, —C(O)—O—, —O—C(O)—, —S(O)0-2—, —C(O)—N(RNB1)—, —N(RNB1)—C(O)—, —O—C(O)—N(RNB1)—, —N(RNB1)—C(O)—O—, —N(RNB2)—C(O)—NRNB1—, —SO2N(RNB1)— or —N(RNB1)SO2—, where RNB1 and RNB2 are independently selected from the group consisting of hydrogen or (1-2C)alkyl;
• QN is selected from the group consisting of hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl(1-2C)alkyl, phenyl, phenyl(1-2C)alkyl, 3- to 8-membered heterocyclyl, [3- to 8-membered heterocyclyl](1-2C)alkyl, 5- or 6-membered heteroaryl, or [5- or 6-membered heteroaryl](1-2C)alkyl.

A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein RNA is selected from halo, nitro, cyano, oxo or a group of the formula:

• wherein:
• LNA is absent or (1-2C)alkylene;
• XNA is absent or is selected from the group consisting of —O—, —C(O)—, —NRNA1—, —C(O)—O—, —O—C(O)—, —S(O)0-2—, —C(O)—N(RNA1)— or —N(RNA1)—C(O)—, where RNA1 is hydrogen or methyl;
• LNB is absent or (1-4C)alkylene;
• XNB is absent or is selected from the group consisting of —O—, —C(O)—, —NRNB1—, —C(O)—O—, —O—C(O)—, —S(O)0-2—, —C(O)—N(RNB1)—, —N(RNB1)—C(O)—, —SO2N(RNB1)— or —N(RNB1)SO2—, where RNB1 and RNB2 are independently selected from the group consisting of hydrogen or methyl;
• QN is selected from the group consisting of hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (3-6C)cycloalkyl, 3- to 6-membered heterocyclyl, [3- to 6-membered heterocyclyl](1-2C)alkyl, 5- or 6-membered heteroaryl, or [5- or 6-membered heteroaryl](1-2C)alkyl.

A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein RNA is selected from halo, nitro, cyano, oxo or a group of the formula:

• wherein:
• LNA is absent or (1-2C)alkylene;
• XNA is absent or is selected from the group consisting of —O—, —C(O)—, —NRNA1—, —C(O)—O—, —O—C(O)—, —S(O)0-2—, —C(O)—N(RNA1)— or —N(RNA1)—C(O)—, where RNA1 is hydrogen or methyl;
• LNB is absent or (1-4C)alkylene;
• XNB is absent or is selected from the group consisting of —O—, —C(O)—, —NRNB1—, —C(O)—O—, —O—C(O)—, —S(O)0-2—, —C(O)—N(RNB1)—, —N(RNB1)—C(O)—, —SO2N(RNB1)— or —N(RNB1)SO2—, where RNB1 and RNB2 are independently selected from the group consisting of hydrogen or methyl;
• QN is selected from the group consisting of hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (3-6C)cycloalkyl, 5- or 6-membered heteroaryl, or [5- or 6-membered heteroaryl](1-2C)alkyl.

A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R2 is hydrogen, halo, cyano, or a group of the formula

• wherein:
• L1 is absent or (1-2C)alkylene;
• X2 is absent or is selected from the group consisting of —O—, —C(O)—, —NR3a—, —C(O)O, —O—C(O)—, —S(O)0-2—, —C(O)—N(R3a)—, —N(R3a)—C(O)—, —O—C(O)—N(R3a)—, —N(R3)—C(O)—O—, —N(R3b)—C(O)—NR3a—, —SO2N(R3a)—, or —N(R3a)SO2—, where R3a and R3b are independently selected from the group consisting of hydrogen or (1-2C)alkyl;
• Q2 is selected from the group consisting of hydrogen, (1-4C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl, phenyl, phenyl(1-4C)alkyl, 3- to 8-membered heterocyclyl, [3- to 8-membered heterocyclyl](1-2C)alkyl, 5- or 6-membered heteroaryl and [5- to 6-membered heteroaryl](1-2C)alkyl, wherein any alkyl, cycloalkyl, cycloalkyl-alkyl, phenyl, phenylalkyl, heterocyclyl, heterocyclyl-alkyl, heteroaryl or heteroaryl-alkyl in Q2 is optionally substituted with one or more R3c groups;
• and
• each R3c group present is independently selected from the group consisting of hydroxy, cyano, oxo, halogen, (1-4C)alkyl, (1-4C)alkoxy, (3-6C)cycloalkyl, or (3-6C)cycloalkyl(1-2C)alkyl, —NR3dR3e, —C(O)—R3d, —C(O)—OR3d, —O—C(O)—R3d, —C(O)—NR3dR3e, —N(R3e)C(O)—R3d, —S(O)0-2R3d—, —S(O)2NR3dR3e, —N(R3e)—S(O)2R3d, phenyl, 5 or 6-membered heteroaryl, or 4 to 6-membered heterocyclyl,
• wherein R3d and R3e are each independently hydrogen, (1-4C)alkyl, (3-6C)cycloalkyl, or (3-6C)cycloalkyl(1-2C)alkyl;
• and wherein any alkyl, alkoxy, cycloalkyl, cycloalkyl-alkyl, phenyl, heteroaryl or heterocyclyl group present in a R3c group, or any alkyl, cycloalkyl, or cycloalkyl-alkyl group present in a R3d or R3e group, is optionally further substituted by one or more substituents independently selected from hydroxy, cyano, halogen, (1-2C)alkyl, —OR3f, —NR3fR3g and —C(O)—R3f, wherein R3a and R3g are both independently selected from hydrogen and (1-2C)alkyl;

A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R2 is hydrogen, cyano, or a group of the formula

• wherein:
• L1 is absent or (1-2C)alkylene;
• X2 is absent or is selected from the group consisting of —O—, —C(O)—, —NR3a—, —C(O)—, —O—C(O)—, —S(O)0-2—, —C(O)—N(R3a)—, —N(R3a)—C(O)—, —SO2N(R3a)— or —N(R3a)SO2—, where R3a is selected from the group consisting of hydrogen or (1-2C)alkyl;
• Q2 is selected from the group consisting of hydrogen, (1-4C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl, phenyl, phenyl(1-4C)alkyl, 4- to 6-membered heterocyclyl, [4- to 6-membered heterocyclyl](1-2C)alkyl, 5- or 6-membered heteroaryl and [5- to 6-membered heteroaryl](1-2C)alkyl, wherein any alkyl, cycloalkyl, cycloalkyl-alkyl, phenyl, phenylalkyl, heterocyclyl, heterocyclyl-alkyl, heteroaryl or heteroaryl-alkyl in Q2 is optionally substituted with one or more R3c groups;
• and
• each R3c group present is independently selected from the group consisting of hydroxy, cyano, oxo, halogen, (1-4C)alkyl, (1-4C)alkoxy, —NR3dR3e, —C(O)—R3d, —C(O)—OR3d, —O—C(O)—R3d, —C(O)—NR3dR3e, —N(R3e)C(O)—R3d, —S(O)0-2R3d—, —S(O)2NR3dR3e, —N(R3e)—S(O)2R3d, phenyl, 5 or 6-membered heteroaryl, or 4 to 6-membered heterocyclyl,
• wherein R3d and R3e are each independently hydrogen or (1-2C)alkyl;
• and wherein any alkyl, alkoxy, cycloalkyl, cycloalkyl-alkyl, phenyl, heteroaryl or heterocyclyl group present in a R3c group is optionally further substituted by one or more substituents independently selected from hydroxy, cyano, halogen, (1-2C)alkyl, or —OR3f, wherein R3f is selected from hydrogen and (1-2C)alkyl.

A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R2 is hydrogen, cyano, or a group of the formula

• wherein:
• X2 is absent or is selected from the group consisting of —NR3a—, —C(O)—O—, —C(O)—N(R3a)— or —N(R3a)—C(O)—, where R3a is selected from the group consisting of hydrogen or methyl;
• Q2 is selected from the group consisting of hydrogen, (1-3C)alkyl, (3-6C)cycloalkyl, phenyl, phenyl(1-4C)alkyl, 5- or 6-membered heteroaryl and [5- to 6-membered heteroaryl](1-2C)alkyl, wherein any alkyl, cycloalkyl, phenyl, phenylalkyl, heteroaryl or heteroaryl-alkyl in Q2 is optionally substituted with one or more R3c groups;
• and
• each R3c group present is independently selected from the group consisting of hydroxy, cyano, halogen, (1-4C)alkyl, (1-4C)alkoxy, or 5 or 6-membered heteroaryl.

A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein Q1 is selected from:

• (i) a group of the formula:
• wherein:
• R4 and R6 are each independently selected from hydrogen, or a group of the formula:
• wherein:
• L2 is absent or (1-3C)alkylene;
• X3 is absent or is selected from the group consisting of —O—, —NR4a—, —S(O)0-2—, —C(O)—N(R4a)—, —N(R4a)—C(O)—, —SO2N(R4a)— or —N(R4a)SO2—, where R4a and R4b are independently selected from the group consisting of hydrogen or (1-2C)alkyl;
• Q3 is selected from the group consisting of hydrogen, (1-4C)alkyl, (3-6C)cycloalkyl, phenyl, 3 to 8-membered heterocyclyl, or 5 or 6-membered heteroaryl, wherein any alkyl, cycloalkyl, cycloalkylalkyl, phenyl, heterocyclyl, or heteroaryl in Q3 is optionally substituted with one or more R4c groups;
• and
• each R4c group present is independently selected from the group consisting of hydroxy, cyano, oxo, halogen, (1-4C)alkyl, (1-4C)alkoxy, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl, —NR4dR4e, —C(O)—R4d, —C(O)—OR4d, —O—C(O)—R4d, —C(O)—NR4dR4e, —N(R4e)C(O)—R4d, —S(O)0-2R4d—, —S(O)2NR4dR4e, or —N(R4e)—S(O)2R4d,
• wherein R4d and R4e are each independently hydrogen or (1-4C)alkyl;
• R5 is:
• a) hydrogen, halo, cyano;
• or
• b) a group of the formula:
• wherein:
• L5a is absent or (1-3C)alkylene;
• X5a is absent or is selected from the group consisting of —O—, —C(O)—, —NR5a1—, —S(O)0-2—, —C(O)—N(R5a1)—, —N(R5a1)—C(O)—, —SO2N(R5a1)— or —N(R5a1)SO2—, where R5a1 and R5a2 are independently selected from the group consisting of hydrogen or (1-2C)alkyl;
• L5b is absent or (1-4C)alkylene;
• X5b is absent or is selected from the group consisting of —O—, —C(O)—, —NR5b1—, —S(O)0-2—, —C(O)—N(R5b1)—, —N(R5b1)—C(O)—, —SO2N(R5b1)— or —N(R5b1)SO2—, where R5b1 and R5b2 are independently selected from the group consisting of hydrogen or (1-2C)alkyl;
• Q5 is selected from the group consisting of hydrogen, (1-6C)alkyl, (3-8C)cycloalkyl, phenyl, 3 to 8-membered heterocyclyl, or 5 or 6-membered heteroaryl and wherein Q5 is optionally substituted with one or more R5c groups;
• and each R5c group present is independently selected from the group consisting of hydroxy, cyano, halogen, (1-6C)alkyl, (1-6C)alkoxy, (3-8C)cycloalkyl (including spiro-fused (3-8C)cycloalkyl), (3-8C)cycloalkyl(1-2C)alkyl, —NR5dR5e, —C(O)—R5d, —C(O)—NR5dR5e, —N(R5e)C(O)—R5d, —S(O)0-2R5d—, —S(O)2NR5dR5e, —N(R5e)—S(O)2R5d, phenyl, 5 or 6-membered heteroaryl, or 4 to 8-membered heterocyclyl,
• wherein R5d and R5e are each independently hydrogen, (1-6C)alkyl, (3-6C)cycloalkyl, or (3-6C)cycloalkyl(1-2C)alkyl;
• and wherein any alkyl, alkoxy, cycloalkyl, cycloalkyl-alkyl, phenyl, heteroaryl or heterocyclyl group present in a R5c group, or any alkyl, cycloalkyl or cycloalkyl-alkyl group present in a R5d or R5e group, is optionally further substituted by one or more substituents independently selected from hydroxy, cyano, halo, R5f, —OR5f, —NR5fR5g and —C(O)—R5f, wherein R5f and R59 are both independently selected from hydrogen, (1-4C)alkyl, hydroxy(1-4C)alkyl, halo(1-4C)alkyl, or (1-2C)alkoxy(1-4C)alkyl;
• R7 is selected from hydrogen, hydroxymethyl, or methoxy;
• or R4 and R5, or R5 and R6 are linked to form a fused phenyl, 5- or 6-membered heteroaryl or 5 to 7-membered heterocyclic ring, which is optionally substituted by one or more substituent groups selected from hydroxy, cyano, halo, (1-2C)alkyl, (1-2C)haloalkyl, (1-2C)alkoxy or (1-2C)haloalkoxy;
• (ii) a group of the formula:
• wherein:
• A1 is selected from N, NR1N, O, S or CR7;
• A2 is selected from N, NR1N, O, S or CR4;
• A3 is selected from N, NR1N, O, S or CR5;
• A4 is selected from N, NR1N, O, S or CR7;
• R1N is selected from hydrogen, (1-4C)alkyl, (2-4C)alkanoyl, phenyl, benzyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl-(1-2C)alkyl, a carbon-linked 4 to 7 membered heterocyclyl, or 4 to 7 membered heterocyclyl(1-2C)alkyl, and wherein any alkyl, alkanoyl, cycloalkyl, cycloalkyl-alkyl, phenyl, benzyl, heterocyclyl, heterocyclyl-alkyl group is optionally substituted with one or more R5c groups defined above;
• R4, R5 and R7 are as defined above;
• and with the proviso that:
• (i) only one of A1, A2, A3 and A4 can be O or S;
• (ii) only one of A1, A2, A3 and A4 can be NRN;
• (iii) 1 to 3 of A1, A2, A3 and A4 can be N;
• (iii) a group of the formula:
• wherein:
• A5 is selected from N or CH;
• A6 is selected from N or CR4;
• A7 is selected from N or CR5;
• A8 is selected from N or CR6;
• A9 is selected from N or CR7;
• R4, R5, R6 and R7 are as defined above;
• and with the proviso that only one of A5, A6, A7, A8 and A9 can be N;
• (iv) a group of the formula:
• wherein:
• p1 is 0 or 1;
• A10 is selected from NH, CH2 or CHR7;
• A11 is selected from NR4N, CH2 or CHR4;
• A12 is selected from NR5N, CH2 or CHR5;
• A13 is selected from NR6N, CH2 or CHR6;
• R4, R5, R6 and R7 are as defined above;
• R4N and R6N are each independently selected from hydrogen or a group of the formula:
• wherein:
• X3N is absent or is selected from the group consisting of:
• —C(O)—, —S(O)0-2— or —C(O)—N(R4a)—;
• wherein R4a is as defined above;
• Q3N is selected from the group consisting of hydrogen, (1-4C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl, heterocyclyl, heteroaryl and,
• wherein any alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl or heteroaryl in Q3 is optionally substituted with one or more R4c groups;
• and
• each R4e group present is as defined above;
• R5N is:
• a) hydrogen;
• b) a group of the formula:
• wherein:
• L5aN is absent or (1-3C)alkylene;
• X5aN is absent or is selected from the group consisting of:
• (iii) —C(O)—, —S(O)0-2—, —C(O)—N(R5a1)— when L5aN is absent;
• or
• (iv) —O—, —C(O)—, —NR5a1—, —C(O)—O—, —O—C(O)—, —S(O)0-2—, —C(O)—N(R5a1)—, —N(R5a1)—C(O)—, —O—C(O)—N(R5a1)—, —N(R5a1)—C(O)—O—, —N(R5a2)—C(O)—NR5a1—, —SO2N(R5a1)— or —N(R5a1)SO2— when L5aN is present;
• where R5a1 and R5a2 are as defined above;
• L5bN is absent or (1-2C)alkylene;
• X5bN is absent or is selected from the group consisting of —O—, —C(O)—, —NR5b1—, —S(O)0-2—, —C(O)—N(R5b1)—, —N(R5b1)—C(O)—, —SO2N(R5b1)— or —N(R5b1)SO2—, where R5b1 and R5b2 are independently selected from the group consisting of hydrogen or (1-2C)alkyl;
• Q5N is selected from the group consisting of:
• (i) hydrogen;
• (ii) (1-4C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-1C)alkyl, phenyl, phenyl(1-2C)alkyl, 5- or 6-membered heteroaryl, 5- or 6-membered heteroaryl(1-2C)alkyl;
• and wherein Q5N is optionally substituted with one or more R5c groups as defined above;
• and with the proviso that one or two of A10, A11, A12 and A13 can be N;
• (v) a group of the formula:
• wherein:
• p1, A10, A11, A12, and A13 are as defined above;
• p2 is 1 to 4;
• A14 is C or N;
• and with the proviso that one of A10, A11, A12 and A13 can be N;
• or:
• RN and one of R4 or R5 are optionally linked to form a linker group L.

A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein Q1 is selected from:

• (i) a group of the formula:
• wherein:
• R4 and R6 are each independently selected from hydrogen, or a group of the formula:
• wherein:
• X3 is absent or is selected from the group consisting of —O—, —NR4a—, —C(O)—N(R4a)—, —N(R4a)—C(O)—, —SO2N(R4a)— or —N(R4a)SO2—, where R4a and R4b are independently selected from the group consisting of hydrogen or (1-2C)alkyl;
• Q3 is selected from the group consisting of hydrogen, (1-4C)alkyl, (3-6C)cycloalkyl, phenyl, 3 to 8-membered heterocyclyl, or 5 or 6-membered heteroaryl, wherein any alkyl, cycloalkyl, cycloalkylalkyl, phenyl, heterocyclyl or heteroaryl in Q3 is optionally substituted with one or more R4c groups;
• and
• each R4c group present is independently selected from the group consisting of hydroxy, cyano, oxo, halogen, (1-4C)alkyl, (1-4C)alkoxy, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl, —NR4dR4e, —C(O)—R4d, —C(O)—OR4d, —O—C(O)—R4d, —C(O)—NR4dR4e, —N(R4e)C(O)—R4d, —S(O)0-2R4d—, —S(O)2NR4dR4e, or —N(R4e)—S(O)2R4d,
• wherein R4d and R4e are each independently hydrogen or (1-2C)alkyl;
• R5 is:
• a) hydrogen, halo, cyano;
• or
• b) a group of the formula:
• wherein:
• X5a is absent or is selected from the group consisting of —O—, —C(O)—, —NR5a1—, —S(O)0-2—, —C(O)—N(R5a1)—, —N(R5a1)—C(O)—, —SO2N(R5a1)— or —N(R5a1)SO2—, where R5a1 and R5a2 are independently selected from the group consisting of hydrogen or (1-2C)alkyl;
• L5b is absent or (1-4C)alkylene;
• X5b is absent or is selected from the group consisting of —O—, —C(O)—, —NR5b1—, —S(O)0-2—, —C(O)—N(R5b1)—, —N(R5b1)—C(O)—, —SO2N(R5b1)— or —N(R5b1)SO2—, where R5b1 and R5b2 are independently selected from the group consisting of hydrogen or (1-2C)alkyl;
• Q5 is selected from the group consisting of hydrogen, (1-6C)alkyl, (3-8C)cycloalkyl, phenyl, 3 to 8-membered heterocyclyl, or 5 or 6-membered heteroaryl and wherein Q5 is optionally substituted with one or more R5c groups;
• and each R5c group present is independently selected from the group consisting of hydroxy, cyano, halogen, (1-6C)alkyl, (1-6C)alkoxy, (3-8C)cycloalkyl (including spiro-fused (3-8C)cycloalkyl), (3-8C)cycloalkyl(1-2C)alkyl, —NR5dR5e, —C(O)—R5d, —C(O)—NR5dR5e, —N(R5e)C(O)—R5d, —S(O)0-2R5d—, —S(O)2NR5dR5e, —N(R5e)—S(O)2R5d, phenyl, 5 or 6-membered heteroaryl, or 4 to 8-membered heterocyclyl,
• wherein R5d and R5e are each independently hydrogen, (1-6C)alkyl, (3-6C)cycloalkyl, or (3-6C)cycloalkyl(1-2C)alkyl;
• and wherein any alkyl, alkoxy, cycloalkyl, cycloalkyl-alkyl, phenyl, heteroaryl or heterocyclyl group present in a R5c group, or any alkyl, cycloalkyl or cycloalkyl-alkyl group present in a R5d or R5e group, is optionally further substituted by one or more substituents independently selected from hydroxy, cyano, halo, R5f, —OR5f, —NR5fR5g and —C(O)—R5f, wherein R5f and R59 are both independently selected from hydrogen, (1-4C)alkyl, hydroxy(1-4C)alkyl, halo(1-4C)alkyl, or (1-2C)alkoxy(1-4C)alkyl;
• R7 is selected from hydrogen, hydroxymethyl, or methoxy;
• or R4 and R5, or R5 and R6 are linked to form a fused phenyl, 5- or 6-membered heteroaryl or 5 to 7-membered heterocyclic ring, which is optionally substituted by one or more substituent groups selected from hydroxy, cyano, halo, (1-2C)alkyl, (1-2C)haloalkyl, (1-2C)alkoxy or (1-2C)haloalkoxy;
• (ii) a group of the formula:
• wherein:
• A1 is selected from N, NR1N, O, S or CR7;
• A2 is selected from N, NR1N, O, S or CR4;
• A3 is selected from N, NR1N, O, S or CR5;
• A4 is selected from N, NR1N, O, S or CR7;
• R1N is selected from hydrogen, (1-4C)alkyl, (2-4C)alkanoyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl-(1-2C)alkyl, a carbon-linked 4 to 7 membered heterocyclyl, or 4 to 7 membered heterocyclyl(1-2C)alkyl, and wherein any alkyl, alkanoyl, cycloalkyl, cycloalkyl-alkyl, heterocyclyl, heterocyclyl-alkyl group is optionally substituted with one or more R5c groups defined above;
• R4, R5 and R7 are as defined above;
• and with the proviso that:
• (i) only one of A1, A2, A3 and A4 can be O or S;
• (ii) only one of A1, A2, A3 and A4 can be NR1N;
• (iii) 1 to 3 of A1, A2, A3 and A4 can be N;
• (iii) a group of the formula:
• wherein:
• A5 is selected from N or CH;
• A6 is selected from N or CR4;
• A7 is selected from N or CR5;
• A8 is selected from N or CR6;
• A9 is selected from N or CR7;
• R4, R5, R6 and R7 are as defined above;
• and with the proviso that only one of A5, A6, A7, A8 and A9 can be N;
• (iv) a group of the formula:
• wherein:
• p1 is 0 or 1;
• A10 is selected from CH2 or CHR7;
• A11 is selected from CH2 or CHR4;
• A12 is selected from NR5N, CH2 or CHR5;
• A13 is selected from CH2 or CHR6;
• R4, R5, R6 and R7 are as defined above;
• R5N is:
• a) hydrogen;
• b) a group of the formula:
• wherein:
• L5aN is absent or (1-3C)alkylene;
• X5aN is absent or is selected from the group consisting of:
• (i) —C(O)—, —S(O)0-2—, —C(O)—N(R5a1)— when L5aN is absent;
• or
• (ii) —O—, —C(O)—, —NR5a1—, —C(O)—O—, —O—C(O)—, —S(O)0-2—, —C(O)—N(R5a1)—, —N(R5a1)—C(O)—, —O—C(O)—N(R5a1)—, —N(R5a1)—C(O)—O—, —N(R5a2)—C(O)—NR5a1—, —SO2N(R5a1)— or —N(R5a1)SO2— when L5aN is present;
• where R5a1 and R5a2 are as defined above;
• L5bN is absent or (1-2C)alkylene;
• X5bN is absent or is selected from the group consisting of —O—, —C(O)—, —NR5b1—, —S(O)0-2—, —C(O)—N(R5b1)—, —N(R5b1)—C(O)—, —SO2N(R5b1)— or —N(R5b1)SO2—, where R5b1 and R5b2 are independently selected from the group consisting of hydrogen or (1-2C)alkyl;
• Q5N is selected from the group consisting of:
• (i) hydrogen;
• (ii) (1-4C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-1C)alkyl, phenyl, phenyl(1-2C)alkyl, 5- or 6-membered heteroaryl, 5- or 6-membered heteroaryl(1-2C)alkyl;
• and wherein Q5N is optionally substituted with one or more R5c groups as defined above;
• and with the proviso that one or two of A10, A11, A12 and A13 can be N;
• (v) a group of the formula:
• wherein:
• p1, A10, A11, A12, and A13 are as defined above;
• p2 is 1 to 4;
• A14 is C or N;
• and with the proviso that one of A10, A11, A12 and A13 can be N;
• or:
• RN and R4 are linked to form a linker group L.

A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein:

• (1) Q1 is selected from:
• (i) a group of the formula:
• wherein:
• R4, R6 and R7 are each independently selected from hydrogen, halo, cyano, or a group of the formula:
• wherein:
• L2 is absent or (1-3C)alkylene;
• X3 is absent or is selected from the group consisting of —O—, —NR4a—, —C(O)—O—, —O—C(O)—, —S(O)0-2—, —C(O)—N(R4a)—, —N(R4a)—C(O)—, —SO2N(R4a)— or —N(R4a)SO2—, where R4a and R4b are independently selected from the group consisting of hydrogen or (1-2C)alkyl;
• Q3 is selected from the group consisting of hydrogen, (1-4C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl, phenyl, phenyl(1-2C)alkyl, 3 to 8-membered heterocyclyl, [3 to 8-membered heterocyclyl](1-2C)alkyl, 5 or 6-membered heteroaryl and 5 or 6-membered heteroaryl(1-2C)alkyl, wherein any alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclyl-alkyl, heteroaryl or heteroaryl-alkyl in Q3 is optionally substituted with one or more R4c groups;
• and
• each R4c group present is independently selected from the group consisting of hydroxy, cyano, oxo, halogen, (1-4C)alkyl, (1-4C)alkoxy, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl, —NR4dR4e, —C(O)—R4d, —C(O)—OR4d, —O—C(O)—R4d, —C(O)—NR4dR4e, —N(R4e)C(O)—R4d, —S(O)0-2R4d—, —S(O)2NR4dR4e, or —N(R4e)—S(O)2R4d,
• wherein R4d and R4e are each independently hydrogen or (1-4C)alkyl;
• and wherein any alkyl, alkoxy, cycloalkyl, cycloalkyl-alkyl group present in a R4c group, or any alkyl group present in a R4d or R4e group, is optionally further substituted by one or more substituents independently selected from hydroxy, cyano, halogen, R4f, —OR4f, —NR4fR4g —C(O)OR4f, —OC(O)R4f, —C(O)NR4fR4g, —NR49C(O)R4f, —S(O)0-2—R4f and —C(O)—R4f, wherein R4f and R4g are both independently selected from hydrogen or (1-2C)alkyl;
• R5 is:
• a) hydrogen, halo, cyano;
• or
• b) a group of the formula:
• wherein:
• L5a is absent or (1-3C)alkylene;
• X5a is absent or is selected from the group consisting of —O—, —C(O)—, —NR5a1—, —C(O)—O—, —O—C(O)—, —S(O)0-2—, —C(O)—N(R5a1)—, —N(R5a1)—C(O)—, —SO2N(R5a1)— or —N(R5a1)SO2—, where R5a1 and R5a2 are independently selected from the group consisting of hydrogen or (1-4C)alkyl;
• L5b is absent or (1-4C)alkylene;
• X5b is absent or is selected from the group consisting of —O—, —C(O)—, —NR5bl—, —C(O)—O—, —O—C(O)—, —S(O)0-2—, —C(O)—N(R5b1)—, —N(R5b1)—C(O)—, —O—C(O)—N(R5b1)—, —N(R5b1)—C(O)—O—, —N(R5b2)—C(O)—NR5b1—, —SO2N(R5b1)— or —N(R5b1)SO2—, where R5b1 and R5b2 are independently selected from the group consisting of hydrogen or (1-4C)alkyl;
• Q5 is selected from the group consisting of hydrogen, (1-6C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl(1-4C)alkyl, phenyl, phenyl(1-2C)alkyl, 3 to 8-membered heterocyclyl, [3 to 8-membered heterocyclyl](1-2C)alkyl, 5 or 6-membered heteroaryl and 5 or 6-membered heteroaryl(1-2C)alkyl and wherein Q5 is optionally substituted with one or more R5cgroups;
• and each R5c group present is independently selected from the group consisting of hydroxy, cyano, oxo, halogen, (1-6C)alkyl, (1-6C)alkoxy, (3-8C)cycloalkyl (including spiro-fused (3-8C)cycloalkyl), or (3-8C)cycloalkyl(1-2C)alkyl, —NR5dR5e, —C(O)—R5d, —C(O)—OR5d, —O—C(O)—R5d, —C(O)—NR5dR5e, —N(R5e)C(O)—R5d, —S(O)0-2R5d—, —S(O)2NR5dR5e, —N(R5e)—S(O)2R5d, phenyl, 5 or 6-membered heteroaryl, or 4 to 8-membered heterocyclyl,
• wherein R5d and R5e are each independently hydrogen, (1-6C)alkyl, (3-6C)cycloalkyl, or (3-6C)cycloalkyl(1-2C)alkyl;
• and wherein any alkyl, alkoxy, cycloalkyl, cycloalkyl-alkyl, phenyl, heteroaryl or heterocyclyl group present in a R5c group, or any alkyl, cycloalkyl or cycloalkyl-alkyl group present in a R5d or R5e group, is optionally further substituted by one or more substituents independently selected from hydroxy, cyano, halo, R5f, —OR5f, —NR5fR5g and —C(O)—R5f, wherein R5f and R59 are both independently selected from hydrogen, (1-4C)alkyl, hydroxy(1-4C)alkyl, halo(1-4C)alkyl, or (1-2C)alkoxy(1-4C)alkyl;
• or R4 and R5, R5 and R6, or R6 and R7 are linked to form a fused phenyl, 5- or 6-membered heteroaryl or 5 to 7-membered heterocyclic ring, which is optionally substituted by one or more substituent groups selected from hydroxy, cyano, halo, (1-2C)alkyl, (1-2C)haloalkyl, (1-2C)alkoxy or (1-2C)haloalkoxy;
• (ii) a group of the formula:
• wherein:
• A1 is selected from N, NR1N, O, S or CR7;
• A2 is selected from N, NR1N, O, S or CR4;
• A3 is selected from N, NR1N, O, S or CR5;
• A4 is selected from N, NR1N, O, S or CR7;
• R1N is selected from hydrogen, (1-4C)alkyl, (2-4C)alkanoyl, phenyl, benzyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl-(1-2C)alkyl, a carbon-linked 4 to 7 membered heterocyclyl, or 4 to 7 membered heterocyclyl(1-2C)alkyl, and wherein any alkyl, alkanoyl, cycloalkyl, cycloalkyl-alkyl, phenyl, benzyl, heterocyclyl, heterocyclyl-alkyl group is optionally substituted with one or more R5c groups defined above;
• R4, R5 and R7 are as defined above;
• and with the proviso that:
• (i) only one of A1, A2, A3 and A4 can be O or S;
• (ii) only one of A1, A2, A3 and A4 can be NR1N;
• (iii) 1 to 3 of A1, A2, A3 and A4 can be N;
• (iii) a group of the formula:
• wherein:
• A5 is selected from N or CH;
• A6 is selected from N or CR4;
• A7 is selected from N or CR5;
• A8 is selected from N or CR6;
• A9 is selected from N or CR7;
• R4, R5, R6 and R7 are as defined above;
• and with the proviso that only one of A5, A6, A7, A8 and A9 can be N;
• (iv) a group of the formula:
• wherein:
• p1 is 0 or 1;
• A10 is selected from NH, CH2 or CHR7;
• A11 is selected from NR4N, CH2 or CHR4;
• A12 is selected from NR5N, CH2 or CHR5;
• A13 is selected from NR6N, CH2 or CHR6;
• R4, R5, R6 and R7 are as defined above;
• R4N and R6N are each independently selected from hydrogen or a group of the formula:
• wherein:
• L2N is absent or (1-3C)alkylene;
• X3N is absent or is selected from the group consisting of:
• (i) —C(O)—, —S(O)0-2— or —C(O)—N(R4a)— when L2 is absent;
• or
• (ii) —O—, —C(O)—, —NR4a—, —C(O)—O—, —O—C(O)—, —S(O)0-2—, —C(O)—N(R4a)—, —N(R4a)—C(O)—, —O—C(O)—N(R4a)—, —N(R4)—C(O)—O—, —N(R4b)—C(O)—NR4a—, —SO2N(R4a)— or —N(R4a)SO2— when L2 is (1-3C)alkylene;
• wherein R4a and R4b are as defined above;
• Q3N is selected from the group consisting of hydrogen, (1-6C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl, heterocyclyl, heterocyclyl(1-2C)alkyl, heteroaryl and heteroaryl(1-2C)alkyl, wherein any alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, heteroaryl or heteroarylalkyl in Q3 is optionally substituted with one or more R4c groups;
• and
• each R4c group present is as defined above;
• R5N is:
• a) hydrogen;
• b) a group of the formula:
• wherein:
• L5aN is absent or (1-3C)alkylene;
• X5aN is absent or is selected from the group consisting of:
• (i) —C(O)—, —S(O)0-2—, —C(O)—N(R5a1)— when L5aN is absent;
• or
• (ii) —O—, —C(O)—, —NR5a1—, —C(O)—O—, —O—C(O)—, —S(O)0-2—, —C(O)—N(R5a1)—, —N(R5a1)—C(O)—, —O—C(O)—N(R5a1)—, —N(R5a1)—C(O)—O—, —N(R5a2)—C(O)—NR5a1—, —SO2N(R5a1)— or —N(R5a1)SO2— when L5aN is present;
• where R5a1 and R5a2 are as defined above;
• L5bN is absent or (1-2C)alkylene;
• X5bN is absent or is selected from the group consisting of —O—, —C(O)—, —NR5bl—, —C(O)—O—, —O—C(O)—, —S(O)0-2—, —C(O)—N(R5b1)—, —N(R5b1)—C(O)—, —SO2N(R5b1)— or —N(R5b1)SO2—, where R5b1 and R5b2 are independently selected from the group consisting of hydrogen or (1-4C)alkyl;
• Q5N is selected from the group consisting of:
• (i) hydrogen;
• (ii) (1-4C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-1C)alkyl, phenyl, phenyl(1-2C)alkyl, 5- or 6-membered heteroaryl, 5- or 6-membered heteroaryl(1-2C)alkyl;
• (iii) a carbon-linked 4 to 8 membered heterocyclyl (when -L5aN, X5aN, L5bN, and X5bN are absent) or a 4 to 8 membered heterocyclyl (when one or more of -L5aN, X5aN, L5bN, and X5bN are present), or [4 to 8 membered heterocyclyl](1-2C)alkyl;
• and wherein Q5N is optionally substituted with one or more R5c groups as defined above;
• and with the proviso that one or two of A10, A11, A12 and A13 can be N;
• (v) a group of the formula:
• wherein:
• p1, A10, A11, A12, and A13 are as defined above;
• p2 is 1 to 5;
• A14 is C or N;
• and with the proviso that one of A10, A11, A12 and A13 can be N;
• or:
• RN and R4 are linked to form a linker group L;
• (2) Q1 is selected from:
• (i) a group of the formula:
• wherein:
• R4, R6 and R7 are each independently selected from hydrogen, or a group of the formula:
• wherein:
• L2 is absent or (1-3C)alkylene;
• X3 is absent or is selected from the group consisting of —O—, —NR4a—, —S(O)0-2—, —C(O)—N(R4a)—, —N(R4a)—C(O)—, —SO2N(R4a)— or —N(R4a)SO2—, where R4a and R4b are independently selected from the group consisting of hydrogen or (1-2C)alkyl;
• Q3 is selected from the group consisting of hydrogen, (1-4C)alkyl, (3-6C)cycloalkyl, (3-8C)cycloalkyl(1-4C)alkyl, phenyl, 3 to 8-membered heterocyclyl, 5 or 6-membered heteroaryl or 5 or 6-membered heteroaryl(1-4C)alkyl wherein any alkyl, cycloalkyl, cycloalkylalkyl, phenyl, heterocyclyl, or heteroaryl in Q3 is optionally substituted with one or more R4c groups;
• and
• each R4c group present is independently selected from the group consisting of hydroxy, cyano, oxo, halogen, (1-4C)alkyl, (1-4C)alkoxy, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl, —NR4dR4e, —C(O)—R4d, —C(O)—OR4d, —O—C(O)—R4d, —C(O)—NR4dR4e, —N(R4e)C(O)—R4d, —S(O)0-2R4d—, —S(O)2NR4dR4e, or —N(R4e)—S(O)2R4d,
• wherein R4d and R4e are each independently hydrogen or (1-4C)alkyl;
• and wherein any alkyl, alkoxy, cycloalkyl, cycloalkyl-alkyl, phenyl, heteroaryl or heterocyclyl group present in a R4c group, or any alkyl group present in a R4d or R4e group, is optionally further substituted by one or more substituents independently selected from hydroxy, cyano, halogen, (1-2C)alkyl, —OR4f, —NR4fR4g, —S(O)0-2—R4f and —C(O)—R4f,
• wherein R4f and R49 are both independently selected from hydrogen and (1-2C)alkyl;
• R5 is:
• a) hydrogen, halo, cyano;
• or
• b) a group of the formula:
• wherein:
• L5a is absent or (1-3C)alkylene;
• X5a is absent or is selected from the group consisting of —O—, —C(O)—, —NR5a1—, —S(O)0-2—, —C(O)—N(R5a1)—, —N(R5a1)—C(O)—, —SO2N(R5a1)— or —N(R5a1)SO2—, where R5a1 and R5a2 are independently selected from the group consisting of hydrogen or (1-2C)alkyl;
• L5b is absent or (1-4C)alkylene;
• X5b is absent or is selected from the group consisting of —O—, —C(O)—, —NR5b1—, —S(O)0-2—, —C(O)—N(R5b1)—, —N(R5b1)—C(O)—, —SO2N(R5b1)— or —N(R5b1)SO2—, where R5b1 and R5b2 are independently selected from the group consisting of hydrogen or (1-2C)alkyl;
• Q5 is selected from the group consisting of hydrogen, (1-6C)alkyl, (3-8C)cycloalkyl, phenyl, 3 to 8-membered heterocyclyl, or 5 or 6-membered heteroaryl and wherein Q5 is optionally substituted with one or more R5c groups;
• and each R5c group present is independently selected from the group consisting of hydroxy, cyano, halogen, (1-6C)alkyl, (1-6C)alkoxy, (3-8C)cycloalkyl (including spiro-fused (3-8C)cycloalkyl), (3-8C)cycloalkyl(1-2C)alkyl, —NR5dR5e, —C(O)—R5d, —C(O)—NR5dR5e, —N(R5e)C(O)—R5d, —S(O)0-2R5d—, —S(O)2NR5dR5e, —N(R5e)—S(O)2R5d, phenyl, 5 or 6-membered heteroaryl, or 4 to 8-membered heterocyclyl,
• wherein R5d and R5e are each independently hydrogen, (1-6C)alkyl, (3-6C)cycloalkyl, or (3-6C)cycloalkyl(1-2C)alkyl;
• and wherein any alkyl, alkoxy, cycloalkyl, cycloalkyl-alkyl, phenyl, heteroaryl or heterocyclyl group present in a R5c group, or any alkyl, cycloalkyl or cycloalkyl-alkyl group present in a R5d or R5e group, is optionally further substituted by one or more substituents independently selected from hydroxy, cyano, halo, R5f, —OR5f, —NR5fR5g and —C(O)—R5f, wherein R5f and R59 are both independently selected from hydrogen, (1-4C)alkyl, hydroxy(1-4C)alkyl, halo(1-4C)alkyl, or (1-2C)alkoxy(1-4C)alkyl;
• or R4 and R5, R5 and R6, or R6 and R7 are linked to form a fused phenyl, 5- or 6-membered heteroaryl or 5 to 7-membered heterocyclic ring, which is optionally substituted by one or more substituent groups selected from hydroxy, cyano, halo, (1-2C)alkyl, (1-2C)haloalkyl, (1-2C)alkoxy or (1-2C)haloalkoxy;
• (ii) a group of the formula:
• wherein:
• A1 is selected from N, NR1N, O, S or CR7;
• A2 is selected from N, NR1N, O, S or CR4;
• A3 is selected from N, NRN, O, S or CR5;
• A4 is selected from N, NR1N, O, S or CR7;
• R1N is selected from hydrogen, (1-4C)alkyl, (2-4C)alkanoyl, phenyl, benzyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl-(1-2C)alkyl, a carbon-linked 4 to 7 membered heterocyclyl, or 4 to 7 membered heterocyclyl(1-2C)alkyl, and wherein any alkyl, alkanoyl, cycloalkyl, cycloalkyl-alkyl, phenyl, benzyl, heterocyclyl, heterocyclyl-alkyl group is optionally substituted with one or more R5c groups defined above;
• R4, R5 and R7 are as defined above;
• and with the proviso that:
• (i) only one of A1, A2, A3 and A4 can be O or S;
• (ii) only one of A1, A2, A3 and A4 can be NR1N;
• (iii) 1 to 3 of A1, A2, A3 and A4 can be N;
• (iii) a group of the formula:
• wherein:
• A5 is selected from N or CH;
• A6 is selected from N or CR4;
• A7 is selected from N or CR5;
• A8 is selected from N or CR6;
• A9 is selected from N or CR7;
• R4, R5, R6 and R7 are as defined above;
• and with the proviso that only one of A5, A6, A7, A8 and A9 can be N;
• (iv) a group of the formula:
• wherein:
• p1 is 0 or 1;
• A10 is selected from NH, CH2 or CHR7;
• A11 is selected from NR4N, CH2 or CHR4;
• A12 is selected from NR5N, CH2 or CHR5;
• A13 is selected from NR6N, CH2 or CHR6;
• R4, R5, R6 and R7 are as defined above;
• R4N and R6N are each independently selected from hydrogen or a group of the formula:
• wherein:
• X3N is absent or is selected from the group consisting of:
• —C(O)—, —S(O)0-2— or —C(O)—N(R4a)—;
• wherein R4a is as defined above;
• Q3N is selected from the group consisting of hydrogen, (1-4C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl, heterocyclyl, heteroaryl and,
• wherein any alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl or heteroaryl in Q3 is optionally substituted with one or more R4c groups;
• and
• each R4c group present is as defined above;
• R5N is:
• a) hydrogen;
• b) a group of the formula:
• wherein:
• L5aN is absent or (1-3C)alkylene;
• X5aN is absent or is selected from the group consisting of:
• (i) —C(O)—, —S(O)0-2—, —C(O)—N(R5a1)— when L5aN is absent;
• or
• (ii) —O—, —C(O)—, —NR5a1—, —C(O)—O—, —O—C(O)—, —S(O)0-2—, —C(O)—N(R5a1)—, —N(R5a1)—C(O)—, —O—C(O)—N(R5a1)—, —N(R5a1)—C(O)—O—, —N(R5a2)—C(O)—NR5a1—, —SO2N(R5a1)— or —N(R5a1)SO2— when L5aN is present;
• where R5a1 and R5a2 are as defined above;
• L5bN is absent or (1-2C)alkylene;
• X5bN is absent or is selected from the group consisting of —O—, —C(O)—, —NR5b1—, —S(O)0-2—, —C(O)—N(R5b1)—, —N(R5b1)—C(O)—, —SO2N(R5b1)— or —N(R5b1)SO2—, where R5b1 and R5b2 are independently selected from the group consisting of hydrogen or (1-2C)alkyl;
• Q5N is selected from the group consisting of:
• (i) hydrogen;
• (ii) (1-4C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-1C)alkyl, phenyl, phenyl(1-2C)alkyl, 5- or 6-membered heteroaryl, 5- or 6-membered heteroaryl(1-2C)alkyl;
• and wherein Q5N is optionally substituted with one or more R5c groups as defined above;
• and with the proviso that one or two of A10, A11, A12 and A13 can be N;
• (v) a group of the formula:
• wherein:
• p1, A10, A11, A12, and A13 are as defined above;
• p2 is 1 to 4;
• A14 is C or N;
• and with the proviso that one of A10, A11, A12 and A13 can be N;
• or:
• RN and R4 are linked to form a linker group L;
• (3) Q1 is selected from:
• (i) a group of the formula:
• wherein:
• R4, R6 and R7 are each independently selected from hydrogen, or a group of the formula:
• wherein:
• L2 is absent or (1-2C)alkylene;
• X3 is absent or is selected from the group consisting of —O—, —NR4a—, —C(O)—N(R4a)—, —N(R4a)—C(O)—, —SO2N(R4a)— or —N(R4a)SO2—, where R4a and R4b are independently selected from the group consisting of hydrogen or (1-2C)alkyl;
• Q3 is selected from the group consisting of hydrogen, (1-4C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-4C)alkyl, phenyl, 3 to 8-membered heterocyclyl, 5 or 6-membered heteroaryl or 5 or 6-membered heteroaryl(1-4C)alkyl wherein any alkyl, cycloalkyl, cycloalkylalkyl, phenyl, heterocyclyl or heteroaryl in Q3 is optionally substituted with one or more R4c groups;
• and
• each R4c group present is independently selected from the group consisting of hydroxy, cyano, oxo, halogen, (1-4C)alkyl, (1-4C)alkoxy, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-2C)alkyl, —NR4dR4e, —C(O)—R4d, —C(O)—OR4d, —O—C(O)—R4d, —C(O)—NR4dR4e, —N(R4e)C(O)—R4d, —S(O)0-2R4d—, —S(O)2NR4dR4e, or —N(R4e)—S(O)2R4d,
• wherein R4d and R4e are each independently hydrogen or (1-2C)alkyl;
• and wherein any alkyl, alkoxy, cycloalkyl, cycloalkyl-alkyl, phenyl, heteroaryl or heterocyclyl group present in a R4c group, or any alkyl group present in a R4d or R4e group, is optionally further substituted by one or more substituents independently selected from hydroxy, cyano, halogen, (1-2C)alkyl, —OR4f, —NR4fR4g, —S(O)0-2—R4f and —C(O)—R4f,
• wherein R4f and R49 are both independently selected from hydrogen and (1-2C)alkyl;
• R5 is:
• a) hydrogen, halo, cyano;
• or
• b) a group of the formula:
• wherein:
• X5a is absent or is selected from the group consisting of —O—, —C(O)—, —NR5a1—, —S(O)0-2—, —C(O)—N(R5a1)—, —N(R5a1)—C(O)—, —SO2N(R5a1)— or —N(R5a1)SO2—, where R5a1 and R5a2 are independently selected from the group consisting of hydrogen or (1-2C)alkyl;
• L5b is absent or (1-4C)alkylene;
• X5b is absent or is selected from the group consisting of —O—, —C(O)—, —NR5b1—, —S(O)0-2—, —C(O)—N(R5b1)—, —N(R5b1)—C(O)—, —SO2N(R5b1)— or —N(R5b1)SO2—, where R5b1 and R5b2 are independently selected from the group consisting of hydrogen or (1-2C)alkyl;
• Q5 is selected from the group consisting of hydrogen, (1-6C)alkyl, (3-8C)cycloalkyl, phenyl, 3 to 8-membered heterocyclyl, or 5 or 6-membered heteroaryl and wherein Q5 is optionally substituted with one or more R5c groups;
• and each R5c group present is independently selected from the group consisting of hydroxy, cyano, halogen, (1-6C)alkyl, (1-6C)alkoxy, (3-8C)cycloalkyl (including spiro-fused (3-8C)cycloalkyl), (3-8C)cycloalkyl(1-2C)alkyl, —NR5dR5e, —C(O)—R5d, —C(O)—NR5dR5e, —N(R5e)C(O)—R5d, —S(O)0-2R5d—, —S(O)2NR5dR5e, —N(R5e)—S(O)2R5d, phenyl, 5 or 6-membered heteroaryl, or 4 to 8-membered heterocyclyl,
• wherein R5d and R5e are each independently hydrogen, (1-6C)alkyl, (3-6C)cycloalkyl, or (3-6C)cycloalkyl(1-2C)alkyl;
• and wherein any alkyl, alkoxy, cycloalkyl, cycloalkyl-alkyl, phenyl, heteroaryl or heterocyclyl group present in a R5c group, or any alkyl, cycloalkyl or cycloalkyl-alkyl group present in a R5d or R5e group, is optionally further substituted by one or more substituents independently selected from hydroxy, cyano, halo, R5f, —OR5f, —NR5fR5g and —C(O)—R5f, wherein R5f and R59 are both independently selected from hydrogen, (1-4C)alkyl, hydroxy(1-4C)alkyl, halo(1-4C)alkyl, or (1-2C)alkoxy(1-4C)alkyl;
• or R4 and R5, R5 and R6, or R6 and R7 are linked to form a fused phenyl, 5- or 6-membered heteroaryl or 5 to 7-membered heterocyclic ring, which is optionally substituted by one or more substituent groups selected from hydroxy, cyano, halo, (1-2C)alkyl, (1-2C)haloalkyl, (1-2C)alkoxy or (1-2C)haloalkoxy;
• (ii) a group of the formula:
• wherein:
• A1 is selected from N, NR1N, O, S or CR7;
• A2 is selected from N, NR1N, O, S or CR4;
• A3 is selected from N, NR1N, O, S or CR;
• A4 is selected from N, NR1N, O, S or CR7;
• R1N is selected from hydrogen, (1-4C)alkyl, (2-4C)alkanoyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl-(1-2C)alkyl, a carbon-linked 4 to 7 membered heterocyclyl, or 4 to 7 membered heterocyclyl(1-2C)alkyl, and wherein any alkyl, alkanoyl, cycloalkyl, cycloalkyl-alkyl, heterocyclyl, heterocyclyl-alkyl group is optionally substituted with one or more R5c groups defined above;
• R4, R5 and R7 are as defined above;
• and with the proviso that:
• (i) only one of A1, A2, A3 and A4 can be O or S;
• (ii) only one of A1, A2, A3 and A4 can be NR1N;
• (iii) 1 to 3 of A1, A2, A3 and A4 can be N;
• (iii) a group of the formula:
• wherein:
• A5 is selected from N or CH;
• A6 is selected from N or CR4;
• A7 is selected from N or CR5;
• A8 is selected from N or CR6;
• A9 is selected from N or CR7;
• R4, R5, R6 and R7 are as defined above;
• and with the proviso that only one of A5, A6, A7, A8 and A9 can be N;
• (iv) a group of the formula:
• wherein:
• p1 is 0 or 1;
• A10 is selected from CH2 or CHR7;
• A11 is selected from CH2 or CHR4;
• A12 is selected from NR5N, CH2 or CHR5;
• A13 is selected from CH2 or CHR6;
• R4, R5, R6 and R7 are as defined above;
• R5N is:
• a) hydrogen;
• b) a group of the formula:
• wherein:
• L5aN is absent or (1-3C)alkylene;
• X5aN is absent or is selected from the group consisting of:
• (i) —C(O)—, —S(O)0-2—, —C(O)—N(R5a1)— when L5aN is absent;
• or
• (ii) —O—, —C(O)—, —NR5a1—, —C(O)—O—, —O—C(O)—, —S(O)0-2—, —C(O)—N(R5a1)—, —N(R5a1)—C(O)—, —O—C(O)—N(R5a1)—, —N(R5a1)—C(O)—O—, —N(R5a2)—C(O)—NR5a1—, —SO2N(R5a1)— or —N(R5a1)SO2— when L5aN is present;
• where R5a1 and R5a2 are as defined above;
• L5bN is absent or (1-2C)alkylene;
• X5bN is absent or is selected from the group consisting of —O—, —C(O)—, —NR5b1—, —S(O)0-2—, —C(O)—N(R5b1)—, —N(R5b1)—C(O)—, —SO2N(R5b1)— or —N(R5b1)SO2—, where R5b1 and R5b2 are independently selected from the group consisting of hydrogen or (1-2C)alkyl;
• Q5N is selected from the group consisting of:
• (i) hydrogen;
• (ii) (1-4C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-1C)alkyl, phenyl, phenyl(1-2C)alkyl, 5- or 6-membered heteroaryl, 5- or 6-membered heteroaryl(1-2C)alkyl;
• and wherein Q5N is optionally substituted with one or more R5c groups as defined above;
• and with the proviso that one or two of A10, A11, A12 and A13 can be N;
• (v) a group of the formula:
• wherein:
• p1, A10, A11, A12, and A13 are as defined above;
• p2 is 1 to 4;
• A14 is C or N;
• and with the proviso that one of A10, A11, A12 and A13 can be N;
• or:
• RN and R4 are linked to form a linker group L;
• (4) Q1 is selected from:
• (i) a group of the formula:
• wherein:
• R4, R6 and R7 are each independently selected from hydrogen, or a group of the formula:
• wherein:
• L2 is absent or (1-2C)alkylene;
• X3 is absent or is selected from the group consisting of —O—, —NR4a—, —C(O)—N(R4a)—, —N(R4a)—C(O)—, —SO2N(R4a)— or —N(R4a)SO2—, where R4a and R4b are independently selected from the group consisting of hydrogen or methyl;
• Q3 is selected from the group consisting of hydrogen, (1-4C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-4C)alkyl, phenyl, 3 to 8-membered heterocyclyl, 5 or 6-membered heteroaryl or 5 or 6-membered heteroaryl(1-4C)alkyl wherein any alkyl, cycloalkyl, cycloalkylalkyl, phenyl, heterocyclyl or heteroaryl in Q3 is optionally substituted with one or more R4c groups;
• and
• each R4c group present is independently selected from the group consisting of hydroxy, cyano, oxo, halogen, methyl, methoxy, (3-6C)cycloalkyl, —NR4dR4e, —C(O)—R4d or —C(O)—OR4d,
• wherein R4d and R4e are each independently hydrogen or methyl;
• and wherein any alkyl, alkoxy, cycloalkyl, cycloalkyl-alkyl, phenyl, heteroaryl or heterocyclyl group present in a R4c group, or any methyl group present in a R4d or R4e group, is optionally further substituted by one or more substituents independently selected from hydroxy, cyano, halogen, (1-2C)alkyl, —OR4f, —NR4fR4g, —S(O)0-2—R4f and —C(O)—R4f,
• wherein R4f and R49 are both independently selected from hydrogen and (1-2C)alkyl;
• R5 is:
• a) hydrogen, halo, cyano;
• or
• b) a group of the formula:
• wherein:
• X5a is absent or is selected from the group consisting of —O—, —C(O)—, —NR5a1— or —N(R5a)—C(O)—, where R5a1 is independently selected from the group consisting of hydrogen or methyl;
• L5b is absent or (1-4C)alkylene;
• X5b is absent or is selected from the group consisting of —O—, —C(O)— or —NR5b1—, where R5b1 and R5b2 are independently selected from the group consisting of hydrogen or (1-2C)alkyl;
• Q5 is selected from the group consisting of hydrogen, (1-6C)alkyl or 3 to 8-membered heterocyclyl and wherein Q5 is optionally substituted with one or more R5c groups;
• and each R5c group present is independently selected from the group consisting of hydroxy, cyano, halogen, methyl, methoxy
• (ii) a group of the formula:
• wherein:
• A1 is selected from N, NR1N, O, S or CR7;
• A2 is selected from N, NRN, O, S or CR4;
• A3 is selected from N, NR1N, O, S or CR;
• A4 is selected from N, NR1N, O, S or CR7;
• R1N is selected from hydrogen, (1-4C)alkyl, (2-4C)alkanoyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl-(1-2C)alkyl, a carbon-linked 4 to 7 membered heterocyclyl, or 4 to 7 membered heterocyclyl(1-2C)alkyl, and wherein any alkyl, alkanoyl, cycloalkyl, cycloalkyl-alkyl, heterocyclyl, heterocyclyl-alkyl group is optionally substituted with one or more R5c groups defined above;
• R4, R5 and R7 are as defined above;
• and with the proviso that:
• (i) only one of A1, A2, A3 and A4 can be O or S;
• (ii) only one of A1, A2, A3 and A4 can be NR1N;
• (iii) 1 to 3 of A1, A2, A3 and A4 can be N;
• (iii) a group of the formula:
• wherein:
• A5 is selected from N or CH;
• A6 is selected from N or CR4;
• A7 is selected from N or CR5;
• A8 is selected from N or CR6;
• A9 is selected from N or CR7;
• R4, R5, R6 and R7 are as defined above;
• and with the proviso that only one of A5, A6, A7, A8 and A9 can be N;
• (iv) a group of the formula:
• wherein:
• p1 is 0 or 1;
• A10 is selected from CH2 or CHR7;
• A11 is selected from CH2 or CHR4;
• A12 is selected from NR5N, CH2 or CHR5;
• A13 is selected from CH2 or CHR6;
• R4, R5, R6 and R7 are as defined above;
• R5N is:
• a) hydrogen;
• b) a group of the formula:
• wherein:
• L5aN is absent or (1-3C)alkylene;
• X5aN is absent or is selected from the group consisting of:
• (i) —C(O)—, —S(O)0-2— or —C(O)—N(R5a1)— when L5aN is absent;
• or
• (ii) —O—, —C(O)—, —NR5a1—, —C(O)—O—, —O—C(O)—, —S(O)0-2—, —C(O)—N(R5a1)—, —N(R5a1)—C(O)—, —O—C(O)—N(R5a1)—, —N(R5a1)—C(O)—O— or —N(R5a2)—C(O)—NR5a1— when L5aN is present;
• where R5a1 and R5a2 are as defined above;
• L5bN is absent or (1-2C)alkylene;
• X5bN is absent or is selected from the group consisting of —O—, —C(O)—, —NR5b1—, —S(O)0-2—, —C(O)—N(R5b1)— or —N(R5b1)—C(O)—, where R5bl and R5b2 are independently selected from the group consisting of hydrogen or (1-2C)alkyl;
• Q5N is selected from the group consisting of:
• (i) hydrogen;
• (ii) (1-4C)alkyl or (3-6C)cycloalkyl;
• and wherein Q5N is optionally substituted with one or more R5c groups as defined above;
• and with the proviso that one or two of A10, A11, A12 and A13 can be N;
• (v) a group of the formula:
• wherein:
• p1, A10, A11, A12, and A13 are as defined above;
• p2 is 1 to 4;
• A14 is C or N;
• and with the proviso that one of A10, A11, A12 and A13 can be N:
• or:
• RN and R4 are linked to form a linker group L;
• (5) Q1 is selected from:
• (i) a group of the formula:
• wherein:
• two of R4, R6 and R7 are hydrogen, and the other is hydrogen or a group of the formula:
• wherein:
• L2 is absent or (1-2C)alkylene;
• X3 is absent or is selected from the group consisting of —O—, —NR4a—, —C(O)—N(R4a)—, —N(R4a)—C(O)—, —SO2N(R4a)— or —N(R4a)SO2—, where R4a and R4b are independently selected from the group consisting of hydrogen or methyl;
• Q3 is selected from the group consisting of hydrogen, (1-4C)alkyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl(1-4C)alkyl, phenyl, 3 to 8-membered heterocyclyl, 5 or 6-membered heteroaryl or 5 or 6-membered heteroaryl(1-4C)alkyl wherein any alkyl, cycloalkyl, cycloalkylalkyl, phenyl, heterocyclyl or heteroaryl in Q3 is optionally substituted with one or more R4c groups;
• and
• each R4c group present is independently selected from the group consisting of hydroxy, cyano, oxo, halogen, methyl, methoxy, (3-6C)cycloalkyl, —NR4dR4e, —C(O)—R4d or —C(O)—OR4d,
• wherein R4d and R4e are each independently hydrogen or methyl;
• and wherein any methyl, methoxy or cycloalkyl, group present in a R4egroup, or any methyl group present in a R4d or R4e group, is optionally further substituted by one or more substituents independently selected from hydroxy, cyano, halogen, —OR4f, —NR4fR49, —S(O)0-2—R4f and —C(O)—R4f, wherein R4f and R49 are both independently selected from hydrogen and (1-2C)alkyl;
• R5 is hydrogen or a group of the formula:
• and
• (ii) a group of the formula:
• wherein:
• A1 is selected from N, NR1N, O, S or CR7;
• A2 is selected from N, NR1N, O, S or CR4;
• A3 is selected from N, NR1N, O, S or CR5;
• A4 is selected from N, NR1N, O, S or CR7;
• R1N is selected from hydrogen, (1-4C)alkyl, (2-4C)alkanoyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl-(1-2C)alkyl, a carbon-linked 4 to 7 membered heterocyclyl, or 4 to 7 membered heterocyclyl(1-2C)alkyl, and wherein any alkyl, alkanoyl, cycloalkyl, cycloalkyl-alkyl, heterocyclyl, heterocyclyl-alkyl group is optionally substituted with one or more R5c groups defined above;
• R4, R5 and R7 are as defined above;
• and with the proviso that:
• (i) only one of A1, A2, A3 and A4 can be O or S;
• (ii) only one of A1, A2, A3 and A4 can be NR1N;
• (iii) 1 to 3 of A1, A2, A3 and A4 can be N;
• (iii) a group of the formula:
• wherein:
• p1 is 0 or 1;
• A10 is selected from CH2 or CHR7;
• A11 is selected from OH2 or CHR4;
• A12 is selected from NR5N, OH2 or CHR;
• A13 is selected from OH2 or CHR6;
• R4, R5, R6 and R7 are as defined above;
• R5N is:
• a) hydrogen;
• b) a group of the formula:
• wherein:
• L5aN is absent or (1-3C)alkylene;
• X5aN is absent or is selected from the group consisting of:
• (i) —C(O)—, —S(O)0-2— or —C(O)—N(R5a1)— when L5aN is absent;
• or
• (ii) —O—, —C(O)—, —NR5a1—, —C(O)—O—, —O—C(O)—, —S(O)0-2—, —C(O)—N(R5a1)—, —N(R5a1)—C(O)—, —O—C(O)—N(R5a1)—, —N(R5a1)—C(O)—O— or —N(R5a2)—C(O)—NR5a1— when L5aN is present;
• where R5a1 and R5a2 are as defined above;
• L5bN is absent or (1-2C)alkylene;
• X5bN is absent or is selected from the group consisting of —O—, —C(O)—, —NR5b1—, —S(O)0-2—, —C(O)—N(R5b1)— or —N(R5b1)—C(O)—, where R5b1 and R5b2 are independently selected from the group consisting of hydrogen or (1-2C)alkyl;
• Q5N is selected from the group consisting of:
• (i) hydrogen;
• (ii) (1-4C)alkyl or (3-6C)cycloalkyl;
• and wherein Q5N is optionally substituted with one or more R5c groups as defined above;
• and with the proviso that one or two of A10, A11, A12 and A13 can be N;
• (iv) a group of the formula:
• wherein:
• p1, A10, A11, A12, and A13 are as defined above;
• p2 is 1 to 4;
• A14 is C or N;
• and with the proviso that one of A10, A11, A12 and A13 can be N;
• or:
• RN and R4 are linked to form a linker group L.

A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein L is a linker group of the formula:

• wherein:
• RL1, RL2, RL3 and RL4 are, at each occurrence, independently selected from hydrogen or (1-2C)alkyl;
• XL or XL1 is selected from —RL5C=CRL6—, ethynylene, —O—, —N(RLN)—, —C(O)—N(RLN)—, —N(RLN)—C(O)—, —C(O)—O—, —O—C(O)—, —S(O)0-2—, —O—C(O)—N(RLN)—, —N(RLN)—C(O)—O—, —N(RLN1)—C(O)—N(RLN)—, —SO2N(RLN)— or —N(RLN)SO2—, wherein RL5 and RL6 are, at each occurrence, independently selected from hydrogen or (1-2C)alkyl, and RLN and RLN1 are each independently selected from hydrogen or (1-2C)alkyl;
• QL is selected from a (4-6C)cycloalkyl, a 4 to 7 membered heterocyclyl or a 5 or 6-membered heteroaryl ring;
• QL1 is selected from a (4-6C)cycloalkyl, a carbon-linked 4 to 7 membered heterocyclyl or a carbon-linked 5 or 6-membered heteroaryl ring;
• a is 1-6;
• b is 0-6;
• c is 1-6;
• d is 0-6;
• and
• e is 1-6;
• and wherein QL and QL1 are optionally substituted by halo, cyan, hydroxy, (1-2C)alkyl, (1-2C)alkoxy, amino, (1-2C)alkylamino, or [di-(1-2C)alkyl]amino.

A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein L is a linker group of the formula:

• wherein:
• XL or XL1 is selected from —RL5C═CRL6—, ethynylene, —O—, —N(RLN)—, —C(O)—N(RLN)—, —N(RLN)—C(O)—, —C(O)—O—, —O—C(O)—, —S(O)0-2—, —O—C(O)—N(RLN)—, —N(RLN)—C(O)—O—, —N(RLN1)—C(O)—N(RLN)—, —SO2N(RLN)— or —N(RLN)SO2—, wherein RL5 and RL6 are, at each occurrence, independently selected from hydrogen or (1-2C)alkyl, and RLN and RLN1 are each independently selected from hydrogen or (1-2C)alkyl;
• QL is selected from a (4-6C)cycloalkyl, a 4 to 7 membered heterocyclyl or a 5 or 6-membered heteroaryl ring;
• QL1 is selected from a (4-6C)cycloalkyl, a carbon-linked 4 to 7 membered heterocyclyl or a carbon-linked 5 or 6-membered heteroaryl ring;
• a is 1-5;
• b is 0-3;
• c is 1-3;
• d is 0-3;
• and
• e is 1-4;
• and wherein QL and QL1 are optionally substituted by halo, cyan, hydroxy, (1-2C)alkyl, (1-2C)alkoxy, amino, (1-2C)alkylamino, or [di-(1-2C)alkyl]amino.

A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein L is a linker group of the formula:

• wherein:
• XL or XL1 is selected from —RL5C=CRL6—, ethynylene, —O—, —N(RLN)—, —C(O)—N(RLN)—, —N(RLN)—C(O)—, —S(O)0-2—, —SO2N(RLN)— or —N(RLN)SO2—, wherein RL5 and RL6 are, at each occurrence, independently selected from hydrogen or methyl, and RLN and RLN1 are each independently selected from hydrogen or methyl;
• QL is selected from a (5-6C)cycloalkyl, a 5 to 7 membered heterocyclyl or a 5 or 6-membered heteroaryl ring;
• QL1 is selected from a (4-6C)cycloalkyl, a carbon-linked 5 to 7 membered heterocyclyl or a carbon-linked 5 or 6-membered heteroaryl ring;
• a is 1-2;
• b is 0-2;
• c is 1-2;
• d is 0-2;
• and
• e is 1-3.

A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein L is:

• (i) a linker group of the formula:
• wherein:
• XL or XL1 is selected from —RL5C=CRL6—, —O—, —N(RLN)—, —C(O)—N(RLN)— or —N(RLN)—C(O)—, wherein RL5 and RL6 are, at each occurrence, independently selected from hydrogen or methyl, and RLN and RLN1 are each independently selected from hydrogen or methyl;
• QL is selected from a (5-6C)cycloalkyl, a 5 to 7 membered heterocyclyl or a 5 or 6-membered heteroaryl ring;
• QL1 is selected from a (4-6C)cycloalkyl, a carbon-linked 5 to 7 membered heterocyclyl or a carbon-linked 5 or 6-membered heteroaryl ring;
• a is 1-2:
• b is 0-2;
• c is 1-2;
• d is 0-2;
• and
• e is 1-3;
• or
• (ii) a linker group of the formula:
• wherein:
• * denotes the point of attachment to the N atom in formula I;
• or
• (iii) a linker group of the formula:
• wherein:
• * denotes the point of attachment to the N atom in formula I.

A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from any one of the following:

• 5-ethynyl-2-((2-methoxyphenyl)amino)-8-phenylpyrido[2,3-d]pyrimidin-7(8H)-one
• N-(2-((2-methoxyphenyl)amino)-7-oxo-8-phenyl-7,8-dihydropyrido[2,3-d]pyrimidin-5-yl)acrylamide
• 5-ethynyl-2-((2-methoxyphenyl)amino)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one
• 8-cyclopentyl-5-ethynyl-2-((2-methoxyphenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one
• 8-(2,4-dimethoxyphenyl)-5-ethynyl-2-((2-methoxyphenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one
• N-(4-((5-ethynyl-7-oxo-8-phenyl-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)-3-methoxyphenyl)-2-methoxy-N-methylacetamide
• 5-ethynyl-2-[(2-methoxyphenyl)amino]-N-methyl-7-oxo-8-phenylpyrido[2,3-d]pyrimidine-6-carboxamide
• 5-ethynyl-2-((2-methoxyphenyl)amino)-7-oxo-8-phenyl-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile
• 5-ethynyl-2-((2-methoxyphenyl)amino)-N,N,8-trimethyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carboxamide
• 5-ethynyl-8-isopropyl-2-((2-methoxyphenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one
• 5-ethynyl-8-(4-methoxyphenyl)-2-((2-methoxyphenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one
• 2-((2-methoxyphenyl)amino)-8-phenyl-5-vinylpyrido[2,3-d]pyrimidin-7(8H)-one
• N-(3-(5-ethynyl-2-((2-methoxyphenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acetamide
• N-(3-(5-ethynyl-2-((2-methoxyphenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)methanesulfonamide
• 2-((2-methoxyphenyl)amino)-7-oxo-8-phenyl-5-vinyl-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile
• 8-(2,4-dimethoxyphenyl)-2-((2-methoxyphenyl)amino)-5-vinylpyrido[2,3-d]pyrimidin-7(8H)-one
• 6-(dimethylamino)-5-ethynyl-2-((2-methoxyphenyl)amino)-8-phenylpyrido[2,3-d]pyrimidin-7(8H)-one
• 8-(2,4-dimethoxyphenyl)-2-((2-methoxyphenyl)amino)-7-oxo-5-vinyl-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile
• 6-amino-5-ethynyl-2-((2-methoxyphenyl)amino)-8-phenylpyrido[2,3-d]pyrimidin-7(8H)-one
• N-(5-ethynyl-2-((2-methoxyphenyl)amino)-7-oxo-8-phenyl-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)acetamide
• N-(3-(5-ethynyl-2-((2-methoxyphenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide
• 5-ethynyl-8-phenyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7(8H)-one
• 6-(2-chlorophenyl)-2-((4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-5-ethynyl-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one
• 2-((4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-5-ethynyl-8-methyl-6-phenylpyrido[2,3-d]pyrimidin-7(8H)-one
• 2-((4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-5-ethynyl-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one
• 6-benzyl-2-((4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-5-ethynyl-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one
• 4-ethynyl-7-((2-methoxyphenyl)amino)-1-phenylpyrimido[4,5-d]pyrimidin-2(1H)-one
• 2-((4-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)amino)-5-ethynyl-8-phenylpyrido[2,3-d]pyrimidin-7(8H)-one
• 8-(2-methoxyphenyl)-2-((2-methoxyphenyl)amino)-5-vinylpyrido[2,3-d]pyrimidin-7(8H)-one
• 5-ethynyl-2-((2-methoxy-4-morpholinophenyl)amino)-8-phenylpyrido[2,3-d]pyrimidin-7(8H)-one
• 6-(2-chlorophenyl)-5-ethynyl-2-((2-methoxyphenyl)amino)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one
• 6-(2-chlorophenyl)-2-((2-methoxyphenyl)amino)-8-methyl-5-vinylpyrido[2,3-d]pyrimidin-7(8H)-one
• 2-((2-methoxyphenyl)amino)-8-methyl-6-phenyl-5-vinylpyrido[2,3-d]pyrimidin-7(8H)-one
• 6-(2-chlorophenyl)-5-ethynyl-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7(8H)-one
• 6-(2,6-dichlorophenyl)-2-((2-methoxyphenyl)amino)-8-methyl-5-vinylpyrido[2,3-d]pyrimidin-7(8H)-one
• 6-(2,6-dichlorophenyl)-5-ethynyl-2-((3-(hydroxymethyl)phenyl)amino)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one
• 6-(2,6-dichlorophenyl)-2-((3-(hydroxymethyl)phenyl)amino)-8-methyl-5-vinylpyrido[2,3-d]pyrimidin-7(8H)-one
• 6-(2-chlorophenyl)-2-((4-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)amino)-5-ethynyl-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one
• 6-(2-chlorophenyl)-2-((4-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)amino)-8-methyl-5-vinylpyrido[2,3-d]pyrimidin-7(8H)-one
• 6-benzyl-2-((4-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)amino)-8-methyl-5-vinylpyrido[2,3-d]pyrimidin-7(8H)-one
• 6-(2,6-dichlorophenyl)-2-((4-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)amino)-8-methyl-5-vinylpyrido[2,3-d]pyrimidin-7(8H)-one
• 6-(2-chlorophenyl)-2-((3-methoxyphenyl)amino)-8-methyl-5-vinylpyrido[2,3-d]pyrimidin-7(8H)-one
• 6-(2-chlorophenyl)-2-((3-(hydroxymethyl)phenyl)amino)-8-methyl-5-vinylpyrido[2,3-d]pyrimidin-7(8H)-one
• N-(3-(5-ethynyl-2-((2-methoxyphenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)cyclopropanesulfonamide
• N-(4-((5-ethynyl-7-oxo-8-phenyl-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)-3-methoxyphenyl)-3-methoxy-N-methylpropanamide
• 6-(2-chlorophenyl)-5-ethynyl-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one
• 6-(2-chlorophenyl)-5-ethynyl-2-((3-(hydroxymethyl)phenyl)amino)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one
• 6-(2-chlorophenyl)-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-8-methyl-5-vinylpyrido[2,3-d]pyrimidin-7(8H)-one
• N-(2-((2-methoxyphenyl)amino)-7-oxo-8-phenyl-5-vinyl-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)acetamide
• 6-(2,6-dichlorophenyl)-2-((4-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)amino)-5-ethynyl-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one
• 6-(2-chlorophenyl)-5-ethynyl-8-methyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one
• 6-(2-chlorophenyl)-2-((4-(2-(dimethylamino)ethoxy)phenyl)amino)-5-ethynyl-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one
• 6-(2-chlorophenyl)-5-ethynyl-2-((3-methoxyphenyl)amino)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one
• 6-(2-chlorophenyl)-8-methyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-5-vinylpyrido[2,3-d]pyrimidin-7(8H)-one
• 6-(2-chlorophenyl)-2-((4-(2-(dimethylamino)ethoxy)phenyl)amino)-8-methyl-5-vinylpyrido[2,3-d]pyrimidin-7(8H)-one
• 2-amino-6-(2-chlorophenyl)-8-methyl-5-vinylpyrido[2,3-d]pyrimidin-7(8H)-one
• 4-ethynyl-7-((2-methoxyphenyl)amino)-1-phenyl-1,6-naphthyridin-2(1H)-one
• 5-ethynyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-8-phenylpyrido[2,3-d]pyrimidin-7(8H)-one
• (R)-2-((4-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)amino)-5-ethynyl-8-(1-propionylpiperidin-3-yl)pyrido[2,3-d]pyrimidin-7(8H)-one
• 6-(2-chlorophenyl)-5-ethynyl-8-methyl-2-((4-(4-methylpiperazin-1-yl)butyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one
• 6-(2-chlorophenyl)-8-methyl-2-((4-(4-methylpiperazin-1-yl)butyl)amino)-5-vinylpyrido[2,3-d]pyrimidin-7(8H)-one
• 5-ethynyl-8-methyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one
• 2-((4-(2-(dimethylamino)ethoxy)phenyl)amino)-5-ethynyl-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one
• 2-((4-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)amino)-5-ethynyl-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one
• 5-ethynyl-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one
• N-((1s,4s)-4-(2-((4-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)amino)-5-ethynyl-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)cyclohexyl)acetamide
• 2-((4-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)amino)-5-ethynyl-8-((1s,4s)-4-(hydroxymethyl)cyclohexyl)pyrido[2,3-d]pyrimidin-7(8H)-one
• 6-(2-chlorophenyl)-2-((4-((2-(dimethylamino)ethyl)(methyl)amino)-3-methylphenyl)amino)-5-ethynyl-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one
• 8-(2,4-dimethoxyphenyl)-2-((4-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)amino)-5-ethynylpyrido[2,3-d]pyrimidin-7(8H)-one
• 2-((4-((2-(dimethylamino)ethyl)(methyl)amino)-3-(1-methyl-1H-pyrazol-4-yl)phenyl)amino)-5-ethynyl-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one
• 6-(2-chloro-5-methoxyphenyl)-2-((4-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)amino)-5-ethynyl-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one
• 6-(2-chloro-5-fluorophenyl)-2-((4-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)amino)-5-ethynyl-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one
• 5-ethynyl-8-methyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one
• 2-((4-(2-(dimethylamino)ethoxy)phenyl)amino)-5-ethynyl-8-phenylpyrido[2,3-d]pyrimidin-7(8H)-one
• 5-ethynyl-2-((2-methoxyphenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one
• 8-(2,4-dimethoxyphenyl)-2-((4-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)amino)-5-vinylpyrido[2,3-d]pyrimidin-7(8H)-one
• 6-(2-chloro-3-fluorophenyl)-2-((4-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)amino)-5-ethynyl-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one
• 2-((4-(4-(dimethylamino)piperidin-1-yl)phenyl)amino)-5-ethynyl-8-phenylpyrido[2,3-d]pyrimidin-7(8H)-one
• 2-((4-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)amino)-5-ethynyl-6-(2-methoxyphenyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one
• 2-((4-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)amino)-5-ethynyl-8-methyl-6-(phenylamino)pyrido[2,3-d]pyrimidin-7(8H)-one
• 5-ethynyl-8-phenyl-2-((4-(piperazin-1-yl)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one
• 2-((4-(4-ethylpiperazin-1-yl)phenyl)amino)-5-ethynyl-8-phenylpyrido[2,3-d]pyrimidin-7(8H)-one
• 5-ethynyl-2-((4-(4-isopropylpiperazin-1-yl)phenyl)amino)-8-phenylpyrido[2,3-d]pyrimidin-7(8H)-one
• 5-ethynyl-2-((4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)-8-phenylpyrido[2,3-d]pyrimidin-7(8H)-one
• 5-ethynyl-2-((4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)amino)-8-phenylpyrido[2,3-d]pyrimidin-7(8H)-one
• 5-ethynyl-2-((4-(1-methylpiperidin-4-yl)phenyl)amino)-8-phenylpyrido[2,3-d]pyrimidin-7(8H)-one
• 2-((4-((2-(dimethylamino)ethyl)(methyl)amino)-3-methylphenyl)amino)-5-ethynyl-8-phenylpyrido[2,3-d]pyrimidin-7(8H)-one
• 6-(3-chloropyridin-4-yl)-2-((4-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)amino)-5-ethynyl-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one
• 2-((4-(4,7-diazaspiro[2.5]octan-7-yl)phenyl)amino)-5-ethynyl-8-phenylpyrido[2,3-d]pyrimidin-7(8H)-one
• 5-ethynyl-2-((1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)amino)-8-phenylpyrido[2,3-d]pyrimidin-7(8H)-one
• 2-((4-(1,4-diazepan-1-yl)phenyl)amino)-5-ethynyl-8-phenylpyrido[2,3-d]pyrimidin-7(8H)-one
• 5-ethynyl-8-phenyl-2-((4-(piperidin-4-yl)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one
• 5-ethynyl-2-((4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-8-phenylpyrido[2,3-d]pyrimidin-7(8H)-one
• 5-ethynyl-8-phenyl-2-((2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one
• 5-ethynyl-2-((4-(3-methylpiperazin-1-yl)phenyl)amino)-8-phenylpyrido[2,3-d]pyrimidin-7(8H)-one
• 8-(3-methoxyphenyl)-2-((2-methoxyphenyl)amino)-5-vinylpyrido[2,3-d]pyrimidin-7(8H)-one
• 5-ethynyl-2-((2-methoxyphenyl)amino)-8-(3-nitrophenyl)pyrido[2,3-d]pyrimidin-7(8H)-one
• 5-ethynyl-2-((2-methoxyphenyl)amino)-8-(4-nitrophenyl)pyrido[2,3-d]pyrimidin-7(8H)-one
• 8-(3-aminophenyl)-5-ethynyl-2-((2-methoxyphenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one
• 5-ethynyl-2-((1-methyl-1H-pyrazol-4-yl)amino)-8-phenylpyrido[2,3-d]pyrimidin-7(8H)-one
• 5-ethynyl-2-((3-(hydroxymethyl)-4-(4-methylpiperazin-1-yl)phenyl)amino)-8-phenylpyrido[2,3-d]pyrimidin-7(8H)-one
• 5-ethynyl-2-((4-(4-(3-(hydroxymethyl)azetidin-1-yl)piperidin-1-yl)phenyl)amino)-8-phenylpyrido[2,3-d]pyrimidin-7(8H)-one
• 5-ethynyl-2-((4-(4-(3-fluoro-3-(hydroxymethyl)azetidin-1-yl)piperidin-1-yl)phenyl)amino)-8-phenylpyrido[2,3-d]pyrimidin-7(8H)-one
• 2-((4-(4-(3-(dimethylamino)azetidin-1-yl)piperidin-1-yl)phenyl)amino)-5-ethynyl-8-phenylpyrido[2,3-d]pyrimidin-7(8H)-one
• 5-ethynyl-2-((2-methoxy-5-(1-methyl-1H-pyrazol-4-yl)-4-morpholinophenyl)amino)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one
• N-(5-((5-ethynyl-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)-2-(4-methylpiperazin-1-yl)phenyl)acetamide
• N-((1s,4s)-4-(5-ethynyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)cyclohexyl)propionamide
• N-((1s,4s)-4-(5-ethynyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)cyclohexyl)isobutyramide
• 2-((3-(5-ethynyl-2-((2-methoxyphenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)amino)-2-oxoethyl acetate
• 8-(4-aminophenyl)-5-ethynyl-2-((2-methoxyphenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one
• N-(4-(5-ethynyl-2-((2-methoxyphenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acetamide
• 2-((4-((3-(Dimethylamino)propyl)(methyl)amino)phenyl)amino)-5-ethynyl-8-phenylpyrido[2,3-d]pyrimidin-7(8H)-one
• 2-((3-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-ethynyl-8-phenylpyrido[2,3-d]pyrimidin-7(8H)-one
• 5-ethynyl-8-isopropyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one
• 8-cyclopentyl-5-ethynyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one
• N-(5-((5-ethynyl-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)-2-(4-methylpiperazin-1-yl)phenyl)propionamide
• 5-ethynyl-2-((1-(methylsulfonyl)piperidin-4-yl)amino)-8-phenylpyrido[2,3-d]pyrimidin-7(8H)-one
• 5-ethynyl-2-((4-morpholinophenyl)amino)-8-phenylpyrido[2,3-d]pyrimidin-7(8H)-one
• N-(4-(5-ethynyl-2-((2-methoxyphenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)methanesulfonamide
• N-(4-(5-ethynyl-2-((2-methoxyphenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)cyclopropanecarboxamide
• 5-ethynyl-2-((4-(4-(3-(methoxymethyl)azetidin-1-yl)piperidin-1-yl)phenyl)amino)-8-phenylpyrido[2,3-d]pyrimidin-7(8H)-one
• N-((1r,4r)-4-(5-ethynyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)cyclohexyl)acetamide
• 2-((4-(5-ethynyl-2-((2-methoxyphenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)amino)-2-oxoethyl acetate
• N-(4-(5-ethynyl-2-((2-methoxyphenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)acrylamide
• 8-(4-methoxyphenyl)-2-((2-methoxyphenyl)amino)-5-vinylpyrido[2,3-d]pyrimidin-7(8H)-one
• 6-cyclopropyl-5-ethynyl-8-methyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one
• 5-ethynyl-6,8-dimethyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one
• 5-ethynyl-2-((4-(4-(3-(2-hydroxypropan-2-yl)azetidin-1-yl)piperidin-1-yl)phenyl)amino)-8-phenylpyrido[2,3-d]pyrimidin-7(8H)-one
• 2-((3-((2-(dimethylamino)ethyl)(methyl)amino)phenyl)amino)-5-ethynyl-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one
• N-(4-(5-ethynyl-2-((2-methoxyphenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)phenyl)propionamide
• 5-ethynyl-2-((2-(hydroxymethyl)phenyl)amino)-8-phenylpyrido[2,3-d]pyrimidin-7(8H)-one
• 5-ethynyl-8-methyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-6-(thiophen-2-yl)pyrido[2,3-d]pyrimidin-7(8H)-one
• 2-(dimethylamino)-N-(3-((5-ethynyl-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)phenyl)-N-methylacetamide
• N-((1r,4r)-4-(5-ethynyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)cyclohexyl)pyridazine-4-carboxamide
• 2-(dimethylamino)-N-(4-((5-ethynyl-7-oxo-8-phenyl-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)-3-methoxyphenyl)acetamide
• 4-(((1s,4s)-4-(5-ethynyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)cyclohexyl)amino)-4-oxobutanoic acid
• N1-((1s,4s)-4-(5-ethynyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)cyclohexyl)-N4,N4-dimethylsuccinamide
• N1-((1s,4s)-4-(5-ethynyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)cyclohexyl)-N3-methylmalonamide
• N1-((1s,4s)-4-(5-ethynyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)cyclohexyl)-N3,N3-dimethylmalonamide
• 3-(dimethylamino)-N-((1s,4s)-4-(5-ethynyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)cyclohexyl)propanamide
• 4-(dimethylamino)-N-((1s,4s)-4-(5-ethynyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)cyclohexyl)butanamide
• N1-((1s,4s)-4-(5-ethynyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)cyclohexyl)-N4-methylsuccinamide
• 3-(((1s,4s)-4-(5-ethynyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)cyclohexyl)amino)-3-oxopropanoic acid
• 2-(dimethylamino)-N-((1s,4s)-4-(5-ethynyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)cyclohexyl)acetamide
• 5-ethynyl-6-methyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-8-phenylpyrido[2,3-d]pyrimidin-7(8H)-one
• 8-(cyclopentylmethyl)-5-ethynyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one
• 5-ethynyl-2-((1′-methyl-[1,4′-bipiperidin]-4-yl)amino)-8-phenylpyrido[2,3-d]pyrimidin-7(8H)-one
• 8-cyclohexyl-5-ethynyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one
• 5-ethynyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-8-(tetrahydro-2H-pyran-4-yl)pyrido[2,3-d]pyrimidin-7(8H)-one
• 5-ethynyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-8-((tetrahydrofuran-3-yl)methyl)pyrido[2,3-d]pyrimidin-7(8H)-one
• (S)-5-ethynyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-8-((5-oxopyrrolidin-2-yl)methyl)pyrido[2,3-d]pyrimidin-7(8H)-one
• 5-ethynyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-8-((tetrahydrofuran-2-yl)methyl)pyrido[2,3-d]pyrimidin-7(8H)-one
• N-((1s,4s)-4-(5-ethynyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)cyclohexyl)-2-(1H-pyrazol-4-yl)acetamide
• 2-(dimethylamino)-N-((1s,4s)-4-(5-ethynyl-2-((2-methoxyphenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)cyclohexyl)acetamide
• 5-ethynyl-8-(2-hydroxycyclopentyl)-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one
• 2-(dimethylamino)-N-((1s,4s)-4-(5-ethynyl-2-((2-methoxyphenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)cyclohexyl)-N-methylacetamide
• N-((1r,4r)-4-(5-ethynyl-6-methyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)cyclohexyl)acetamide
• N-((1s,4s)-4-(5-ethynyl-6-methyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7-oxopyrido[2,3-d]pyrimidin-8(7H)-yl)cyclohexyl)acetamide
• 5-ethynyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-8-(2-oxopyrrolidin-3-yl)pyrido[2,3-d]pyrimidin-7(8H)-one
• 5-ethynyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-8-(tetrahydrofuran-3-yl)pyrido[2,3-d]pyrimidin-7(8H)-one
• 5-ethynyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-8-(pyrrolidin-3-yl)pyrido[2,3-d]pyrimidin-7(8H)-one
• 5-ethynyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-8-(1-methylpyrrolidin-3-yl)pyrido[2,3-d]pyrimidin-7(8H)-one
• 5-ethynyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-8-(5-oxopyrrolidin-3-yl)pyrido[2,3-d]pyrimidin-7(8H)-one
• 8-((1H-pyrazol-5-yl)methyl)-5-ethynyl-6-methyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one
• 5-ethynyl-6-methyl-8-((1-methyl-1H-pyrazol-3-yl)methyl)-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one
• 8-((1H-imidazol-5-yl)methyl)-5-ethynyl-6-methyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one
• 5-ethynyl-6-methyl-8-((1-methyl-1H-pyrazol-5-yl)methyl)-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one
• 5-ethynyl-8-(isoxazol-5-ylmethyl)-6-methyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one
• 5-ethynyl-6-methyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-8-(pyridin-3-ylmethyl)pyrido[2,3-d]pyrimidin-7(8H)-one
• 8-(cyclopentylmethyl)-5-ethynyl-6-methyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one
• 5-ethynyl-8-(1-methyl-5-oxopyrrolidin-3-yl)-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one
• 5-ethynyl-8-((1-methyl-1H-pyrazol-3-yl)methyl)-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one
• 5-ethynyl-6-methyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-8-(oxazol-2-ylmethyl)pyrido[2,3-d]pyrimidin-7(8H)-one
• 5-ethynyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-8-((2-oxopyrrolidin-3-yl)methyl)pyrido[2,3-d]pyrimidin-7(8H)-one
• 15-ethynyl-17,18-dihydro-4-oxa-2-aza-1(2,8)-pyrido[2,3-d]pyrimidina-3(1,3)-benzenacycloheptaphan-17-one
• (Z)-15-ethynyl-17,18-dihydro-4-oxa-2-aza-1(2,8)-pyrido[2,3-d]pyrimidina-3(1,3)-benzenacyclooctaphan-6-en-17-one
• (Z)-15-ethynyl-34-(4-methylpiperazin-1-yl)-17,18-dihydro-4-oxa-2-aza-1(2,8)-pyrido[2,3-d]pyrimidina-3(1,3)-benzenacyclooctaphan-6-en-17-one
• 15-ethynyl-34-(4-methylpiperazin-1-yl)-17,18-dihydro-4-oxa-2-aza-1(2,8)-pyrido[2,3-d]pyrimidina-3(1,3)-benzenacyclooctaphan-17-one;
• 5-Ethynyl-6-methyl-2-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-8-(1,2-oxazol-4-ylmethyl)pyrido[2,3-d]pyrimidin-7-one;
• 5-Ethynyl-6-methyl-2-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-8-(1,3-oxazol-5-ylmethyl)pyrido[2,3-d]pyrimidin-7-one;
• 5-Ethynyl-8-(1H-imidazol-2-ylmethyl)-6-methyl-2-{[4-(4-methylpiperazin-1-yl)phenyl]amino}pyrido[2,3-d]pyrimidin-7-one;
• 5-Ethynyl-6-methyl-2-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-8-(pyridin-2-ylmethyl)pyrido[2,3-d]pyrimidin-7-one;
• 5-Ethynyl-6-methyl-2-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-8-(pyridin-4-ylmethyl)pyrido[2,3-d]pyrimidin-7-one;
• 5-Ethynyl-6-methyl-2-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-8-[(1-methylpyrazol-4-yl)methyl]pyrido[2,3-d]pyrimidin-7-one;
• 8-Cyclopentyl-5-ethynyl-2-[(3-([3-(methanesulfonylmethyl)azetidin-1-yl]methylphenyl)amino]pyrido[2,3-d]pyrimidin-7-one;
• 8-Cyclopentyl-5-ethynyl-2-[(3-([3-(methanesulfonylmethyl)pyrrolidin-1-yl]methylphenyl)amino]pyrido[2,3-d]pyrimidin-7-one;
• 8-Cyclopentyl-5-ethynyl-2-[(3-([4-(methanesulfonylmethyl)piperidin-1-yl]methylphenyl)amino]pyrido[2,3-d]pyrimidin-7-one;
• 8-Cyclopentyl-5-ethynyl-2-[(2-methyl-1,3-dihydroisoindol-4-yl)amino]pyrido[2,3-d]pyrimidin-7-one;
• 8-Cyclopentyl-5-ethynyl-2-[(2-methyl-3,4-dihydro-1H-isoquinolin-5-yl)amino]pyrido[2,3-d]pyrimidin-7-one;
• (Z)-15-ethynyl-16-methyl-17,18-dihydro-4-oxa-2-aza-1(2,8)-pyrido[2,3-d]pyrimidina-3(1,3)-benzenacyclooctaphan-6-en-17-one:
• 15-ethynyl-16-methyl-17,18-dihydro-4-oxa-2-aza-1(2,8)-pyrido[2,3-d]pyrimidina-3(1,3)-benzenacyclooctaphan-17-one;
• (51R,53S)-35-ethynyl-37,33-dihydro-7-oxa-2-aza-3(2,8)-pyrido[2,3-d]pyrimidina-1(1,3)-benzena-5(1,3)-cyclopentanacycloheptaphan-37-one;
• 15-Ethynyl-17,18-dihydro-4-oxa-2-aza-1(2,8)-pyrido[2,3-d]pyrimidina-3(1,3)-benzenacyclooctaphan-17-one;
• 15-Ethynyl-16-methyl-34-(4-methylpiperazin-1-yl)-17,18-dihydro-4-oxa-2-aza-1(2,8)-pyrido[2,3-d]pyrimidina-3(1,3)-benzenacyclooctaphan-17-one;
• (Z)-15-ethynyl-17,18-dihydro-5-oxa-2-aza-1(2,8)-pyrido[2,3-d]pyrimidina-3(1,3)-benzenacyclononaphan-7-en-17-one;
• 15-Ethynyl-34-(4-methylpiperazin-1-yl)-17,18-dihydro-5-oxa-2-aza-1(2,8)-pyrido[2,3-d]pyrimidina-3(1,3)-benzenacyclooctaphan-17-one;
• 15-Ethynyl-34-(4-methylpiperazin-1-yl)-17,18-dihydro-2,6-diaza-1(2,8)-pyrido[2,3-d]pyrimidina-3(1,3)-benzenacyclooctaphane-17,5-dione;
• 15-Ethynyl-34-(4-methylpiperazin-1-yl)-17,18-dihydro-2,4-diaza-1(2,8)-pyrido[2,3-d]pyrimidina-3(1,3)-benzenacyclooctaphan-17-one;
• 15-Ethynyl-34-(4-methylpiperazin-1-yl)-17,18-dihydro-2,5-diaza-1(2,8)-pyrido[2,3-d]pyrimidina-3(1,3)-benzenacyclooctaphan-17-one;
• 15-Ethynyl-34-(4-methylpiperazin-1-yl)-17,18-dihydro-4-oxa-2-aza-1(2,8)-pyrido[2,3-d]pyrimidina-3(1,3)-benzenacyclononaphan-17-one;
• N-(5-((5-ethynyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)-2-(4-methylpiperazin-1-yl)benzyl)acrylamide;
• 8-cyclopentyl-5-ethynyl-2-((2-(3-((methylsulfonyl)methyl)piperidin-1-yl)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one;
• 8-cyclopentyl-5-ethynyl-2-((3-(methyl((1s,3s)-3-((methylsulfonyl)methyl)cyclobutyl)amino)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one;
• 8-cyclopentyl-5-ethynyl-2-((3-(methyl((1s,4s)-4-((methylsulfonyl)methyl)cyclohexyl)amino)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one;
• 8-cyclopentyl-5-ethynyl-2-((3-(methyl((1r,3r)-3-((methylsulfonyl)methyl)cyclobutyl)amino)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one;
• 8-cyclopentyl-5-ethynyl-2-((3-(methyl((1r,4r)-4-((methylsulfonyl)methyl)cyclohexyl)amino)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one;
• 5-ethynyl-8-methyl-2-((4-(4-methylpiperazin-1-yl)-3-propoxyphenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one;
• 5-ethynyl-2-((3-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one;
• 2-((3-(2-cyclopentylethoxy)-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-ethynyl-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one;
• 2-((3-(2-cyclopentylethoxy)-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-ethynyl-8-((1-methyl-1H-pyrazol-3-yl)methyl)pyrido[2,3-d]pyrimidin-7(8H)-one;
• 2-((3-(cyclopentylmethoxy)-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-ethynyl-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one;
• 2-((3-(3-cyclopentylpropoxy)-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-ethynyl-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one;
• 2-((3-(2-cyclohexylethoxy)-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-ethynyl-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one;
• 5-ethynyl-8-methyl-2-((4-(4-methylpiperazin-1-yl)-3-phenethoxyphenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one;
• 2-((3-(cyclopentyloxy)-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-ethynyl-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one;
• 5-ethynyl-2-((3-(isopentyloxy)-4-(4-methylpiperazin-1-yl)phenyl)amino)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one;
• 2-cyclopentyl-N-(5-((5-ethynyl-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)-2-(4-methylpiperazin-1-yl)phenyl)acetamide;
• N-(cyclopentylmethyl)-5-((5-ethynyl-8-methyl-7-oxo-7,8-dihydropyrido[2, 3-d]pyrimidin-2-yl)amino)-2-(4-methylpiperazin-1-yl)benzenesulfonamide;
• 1-cyclopentyl-3-(5-((5-ethynyl-8-methyl-7-oxo-7,8-dihydropyrido[2, 3-d]pyrimidin-2-yl)amino)-2-(4-methylpiperazin-1-yl)phenyl)urea;
• 5-ethynyl-8-methyl-2-((3-(2-(1-methyl-1H-pyrazol-3-yl)ethoxy)-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one;
• N-(cyclopentylmethyl)-5-((5-ethynyl-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)-2-(4-methylpiperazin-1-yl)benzamide;
• 15-ethynyl-34-(4-methylpiperazin-1-yl)-17,18-dihydro-2,4-diaza-1(2,8)-pyrido[2,3-d]pyrimidina-3(1,3)-benzenacyclooctaphane-17,5-dione;
• 15-ethynyl-5-methyl-34-(4-methylpiperazin-1-yl)-17,18-dihydro-2,5-diaza-1(2,8)-pyrido[2,3-d]pyrimidina-3(1,3)-benzenacyclooctaphane-17,6-dione;
• 15-ethynyl-34-(4-methylpiperazin-1-yl)-17,18-dihydro-2,5-diaza-1(2,8)-pyrido[2,3-d]pyrimidina-3(1,3)-benzenacyclooctaphane-17,4-dione;
• 15-ethynyl-4-methyl-34-(4-methylpiperazin-1-yl)-17,18-dihydro-2,4-diaza-1(2,8)-pyrido[2,3-d]pyrimidina-3(1,3)-benzenacyclooctaphane-17,5-dione;
• 15-ethynyl-5-methyl-34-(4-methylpiperazin-1-yl)-17,18-dihydro-2,5-diaza-1(2,8)-pyrido[2,3-d]pyrimidina-3(1,3)-benzenacyclooctaphan-17-one:
• 15-ethynyl-34-(4-methylpiperazin-1-yl)-17,18-dihydro-2,6-diaza-1(2,8)-pyrido[2,3-d]pyrimidina-3(1,3)-benzenacyclooctaphane-17,7-dione;
• 15-ethynyl-9-methyl-34-(4-methylpiperazin-1-yl)-17,18-dihydro-4-oxa-2-aza-1(2,8)-pyrido[2,3-d]pyrimidina-3(1,3)-benzenacyclononaphan-17-one;
• 15-ethynyl-16-methyl-34-(4-methylpiperazin-1-yl)-17,18-dihydro-4-oxa-2-aza-1(2,8)-pyrido[2,3-d]pyrimidina-3(1,3)-benzenacyclononaphan-17-one;
• 15-ethynyl-34-(4-methylpiperazin-1-yl)-17,18-dihydro-4-oxa-2-aza-1(2,8)-pyrido[2,3-d]pyrimidina-3(1,3)-benzenacyclodecaphan-17-one;
• 15-ethynyl-34-(4-methylpiperazin-1-yl)-17,18-dihydro-5-oxa-2-aza-1(2,8)-pyrido[2,3-d]pyrimidina-3(1,3)-benzenacyclononaphan-17-one;
• 15-ethynyl-34-(4-methylpiperazin-1-yl)-17,18-dihydro-4,7-dioxa-2-aza-1(2,8)-pyrido[2,3-d]pyrimidina-3(1,3)-benzenacyclononaphan-17-one;
• (51S,53R)-35-ethynyl-14-(4-methylpiperazin-1-yl)-37,38-dihydro-7-oxa-2-aza-3(2,8)-pyrido[2,3-d]pyrimidina-1(1,3)-benzena-5(1,3)-cyclopentanacycloheptaphan-37-one;
• 15-ethynyl-34-(4-methylpiperazin-1-yl)-17,18-dihydro-4-thia-2,5-diaza-1(2,8)-pyrido[2,3-d]pyrimidina-3(1,3)-benzenacyclooctaphan-17-one 4,4-dioxide;
• 15-ethynyl-34-(4-isopropylpiperazin-1-yl)-17,18-dihydro-2,4-diaza-1(2,8)-pyrido[2,3-d]pyrimidina-3(1,3)-benzenacyclooctaphane-17,5-dione;
• 15-ethynyl-34-(4-(2-methoxyethyl)piperazin-1-yl)-17,18-dihydro-2,4-diaza-1(2,8)-pyrido[2,3-d]pyrimidina-3(1,3)-benzenacyclooctaphane-17,5-dione;
• 15-ethynyl-34-(4-methylpiperazin-1-yl)-17,18-dihydro-2,5-diaza-1(2,8)-pyrido[2,3-d]pyrimidina-3(1,3)-benzenacyclononaphane-17,6-dione;
• 15-ethynyl-34-(4-methyl-1,4-diazepan-1-yl)-17,18-dihydro-2,4-diaza-1(2,8)-pyrido[2,3-d]pyrimidina-3(1,3)-benzenacyclooctaphane-17,5-dione;
• (R)-15-ethynyl-8-methyl-34-(4-methylpiperazin-1-yl)-17,18-dihydro-4-oxa-2-aza-1(2,8)-pyrido[2,3-d]pyrimidina-3(1,3)-benzenacyclooctaphan-17-one;
• 15-ethynyl-34-(4-methylpiperazin-1-yl)-17,18-dihydro-6-oxa-2-aza-1(2,8)-pyrido[2,3-d]pyrimidina-3(1,3)-benzenacyclooctaphan-17-one;
• and
• 15-ethynyl-34-(4-(2-methoxyethyl)piperazin-1-yl)-17,18-dihydro-4-oxa-2-aza-1(2,8)-pyrido[2,3-d]pyrimidina-3(1,3)-benzenacyclooctaphan-17-one.